<SEC-DOCUMENT>0000059478-26-000077.txt : 20260805
<SEC-HEADER>0000059478-26-000077.hdr.sgml : 20260805
<ACCEPTANCE-DATETIME>20260805070509
ACCESSION NUMBER:		0000059478-26-000077
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20260805
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20260805
DATE AS OF CHANGE:		20260805

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ELI LILLY & Co
		CENTRAL INDEX KEY:			0000059478
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				350470950
		STATE OF INCORPORATION:			IN
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-06351
		FILM NUMBER:		261241293

	BUSINESS ADDRESS:	
		STREET 1:		LILLY CORPORATE CTR
		STREET 2:		DROP CODE 1094
		CITY:			INDIANAPOLIS
		STATE:			IN
		ZIP:			46285
		BUSINESS PHONE:		3172762000

	MAIL ADDRESS:	
		STREET 1:		LILLY CORPORATE CENTER
		STREET 2:		DROP CODE 1094
		CITY:			INDIANAPOLIS
		STATE:			IN
		ZIP:			46285

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	LILLY ELI & CO
		DATE OF NAME CHANGE:	19941024
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>lly-20260805.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:019f8a77-cc87-70d8-bcd7-b8b7964653b4,g:c8da2307-0382-494c-ac1c-f110104979d9,d:4dd6ecbba3874645b9b2723df0c1e80e-->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2026" xmlns:us-gaap="http://fasb.org/us-gaap/2026" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:lly="http://www.lilly.com/20260805" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>lly-20260805</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-45">0000059478</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" id="f-46">false</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="lly-20260805.xsd"/></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2026-08-05</xbrli:startDate><xbrli:endDate>2026-08-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-08-05</xbrli:startDate><xbrli:endDate>2026-08-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A2.125NotesDueJune32030Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-08-05</xbrli:startDate><xbrli:endDate>2026-08-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A625Notesdue2031Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-08-05</xbrli:startDate><xbrli:endDate>2026-08-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A500NotesDue2033Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-08-05</xbrli:startDate><xbrli:endDate>2026-08-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A6.77NotesDueJanuary12036Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-08-05</xbrli:startDate><xbrli:endDate>2026-08-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A1625NotesDue2043Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-08-05</xbrli:startDate><xbrli:endDate>2026-08-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A1.700Notesdue2049Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-08-05</xbrli:startDate><xbrli:endDate>2026-08-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A1125NotesDue2051Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-08-05</xbrli:startDate><xbrli:endDate>2026-08-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-10"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A1375NotesDue2061Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-08-05</xbrli:startDate><xbrli:endDate>2026-08-05</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i4dd6ecbba3874645b9b2723df0c1e80e_1"></div><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:1.2pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:74.338%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.767%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:14pt;font-weight:700;line-height:100%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:14pt;font-weight:700;line-height:100%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Washington, D.C. 20549</span></div></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.146%"><tr><td style="width:1.0%"/><td style="width:26.721%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:44.619%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.360%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-top:8.2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">8-K</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:18pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.146%"><tr><td style="width:1.0%"/><td style="width:26.721%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:44.619%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.360%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-bottom:2.2pt;margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:14pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">Pursuant to Section&#160;13 or 15(d)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">of the Securities Exchange Act of 1934</span></div><div style="margin-top:13.2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">Date of Report (Date of Earliest Event Reported): <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-2">August 5, 2026</ix:nonNumeric></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.146%"><tr><td style="width:1.0%"/><td style="width:26.721%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:44.619%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.360%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-top:7pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:24pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-3">ELI LILLY AND COMPANY</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"> (Exact Name of Registrant as Specified in its Charter)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.146%"><tr><td style="width:1.0%"/><td style="width:26.721%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:44.619%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.360%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.978%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.883%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.885%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-4">Indiana</ix:nonNumeric></span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">001-06351</ix:nonNumeric></span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-6">35-0470950</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">(State or Other Jurisdiction<br/>of Incorporation)</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">(Commission<br/>File Number)</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">(I.R.S. Employer<br/>Identification No.)</span></td></tr><tr><td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"/><td colspan="6" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.128%"><tr><td style="width:1.0%"/><td style="width:17.895%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.895%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:59.025%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.055%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.430%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-7">Lilly Corporate Center</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-8">Indianapolis,</ix:nonNumeric></span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="f-9">Indiana</ix:nonNumeric></span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-10">46285</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="6" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">(Address of Principal Executive Offices)</span></td><td colspan="6" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">(Zip Code)</span></td><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Registrant&#8217;s Telephone Number, Including Area Code: (<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-11">317</ix:nonNumeric>) <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-12">276-2000</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Not Applicable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"> (Former Name or Former Address, if Changed Since Last Report.)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:13.2pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">see</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> General Instruction A.2.):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:2.987%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.987%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:90.726%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox" id="f-13">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:3.005%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.565%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:91.130%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox" id="f-14">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:2.853%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.853%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:90.994%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox" id="f-15">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:2.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.864%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:91.265%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox" id="f-16">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr></table></div><div style="margin-top:1pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act: </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="margin-bottom:1pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:31.502%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:27.847%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:36.183%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-2" name="dei:Security12bTitle" id="f-17">Common Stock (no par value)</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-2" name="dei:TradingSymbol" id="f-18">LLY</ix:nonNumeric></span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-2" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-19">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-3" name="dei:Security12bTitle" id="f-20">2.125% Notes due 2030</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-3" name="dei:TradingSymbol" id="f-21">LLY30</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-3" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-22">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-4" name="dei:Security12bTitle" id="f-23">0.625% Notes due 2031</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-4" name="dei:TradingSymbol" id="f-24">LLY31</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-4" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-25">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-5" name="dei:Security12bTitle" id="f-26">0.500% Notes due 2033</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-5" name="dei:TradingSymbol" id="f-27">LLY33</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-5" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-28">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-6" name="dei:Security12bTitle" id="f-29">6.77% Notes due 2036</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-6" name="dei:TradingSymbol" id="f-30">LLY36</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-6" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-31">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-7" name="dei:Security12bTitle" id="f-32">1.625% Notes due 2043</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-7" name="dei:TradingSymbol" id="f-33">LLY43</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-7" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-34">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-8" name="dei:Security12bTitle" id="f-35">1.700% Notes due 2049</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-8" name="dei:TradingSymbol" id="f-36">LLY49A</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-8" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-37">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-9" name="dei:Security12bTitle" id="f-38">1.125% Notes due 2051</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-9" name="dei:TradingSymbol" id="f-39">LLY51</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-9" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-40">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-10" name="dei:Security12bTitle" id="f-41">1.375% Notes due 2061</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-10" name="dei:TradingSymbol" id="f-42">LLY61</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-10" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-43">New York Stock Exchange</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR &#167;230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR &#167;240.12b-2).</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="f-44">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;&#9744;</span></div><div style="text-indent:36pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:8pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div id="i4dd6ecbba3874645b9b2723df0c1e80e_7"></div><div style="-sec-extract:summary"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 2.02.  Results of Operations and Financial Condition.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The information in this Item 2.02, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed &#8220;filed&#8221; for the purposes of Section 18 of the Securities Exchange Act of 1934 (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that Section and shall not be incorporated by reference into any registration statement or other document filed pursuant to the Securities Act of 1933 or the Exchange Act, except as otherwise expressly stated in such filing.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Attached hereto as Exhibit 99.1 and incorporated by reference into this Item 2.02 is a copy of the press release, dated August 5, 2026, announcing the financial results of Eli Lilly and Company for the quarter ended June 30, 2026.</span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">Item 9.01.  Financial Statements and Exhibits.</span></div><div><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.497%"><tr><td style="width:1.0%"/><td style="width:15.055%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:82.745%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Exhibit No.</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Description</span></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="q226lillysalesandearningsp.htm">99.1</a></span></div></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="q226lillysalesandearningsp.htm">Press Release of Eli Lilly and Company, dated</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="q226lillysalesandearningsp.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="q226lillysalesandearningsp.htm">August 5</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="q226lillysalesandearningsp.htm">,  2026.</a></span></div></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (embedded within the Inline XBRL document).</span></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="margin-top:6pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:49.707%"><tr><td style="width:1.0%"/><td style="width:15.076%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.858%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:80.666%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">ELI LILLY AND COMPANY</span></td></tr><tr><td colspan="9" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">(Registrant)</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">By:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Donald A. Zakrowski</span></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Name:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Donald A. Zakrowski</span></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Title:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Senior Vice President, Finance, and <br/>Chief Accounting Officer</span></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Date: </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">August 5, 2026</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>q226lillysalesandearningsp.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2026 Workiva -->
<title>Document</title></head><body><div id="id7ff9e57898d493f8c8538147afd934e_1"></div><div style="min-height:103.68pt;width:100%"><div style="text-align:right"><img alt="logoa31a.jpg" src="logoa31a.jpg" style="height:70px;margin-bottom:5pt;vertical-align:text-bottom;width:112px"></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">August&#160;5, 2026</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For release&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immediately</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Refer to&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Megan MacCauley&#59; maccauley_megan&#64;lilly.com (Media)</font></div><div style="padding-left:36pt;text-indent:49.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mike Czapar&#59; czapar_michael_c&#64;lilly.com (Investors)</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Lilly reports second-quarter 2026 financial results, raise</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">s full-year guidance, and highlights continued growth and pipeline progress</font></div><div style="text-align:center"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#212121;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:13.8pt">Revenue in Q2 2026 increased 48% to $23.0 billion driven primarily by Mounjaro and Zepbound volume.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font><br></font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#212121;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Q2 2026 EPS increased by 26% to $7.94 on a reported basis and increased by 33% to $8.38 on a non-GAAP basis. Q2 2026 reported and non-GAAP EPS included $3.03 of acquired IPR&#38;D charges compared to $0.14 in Q2 2025.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Increased 2026 full-year revenue guidance to be in the range of $85.0 billion to $87.0 billion and raised underlying non-GAAP EPS guidance for the full year by $2.78 at the midpoint, which was more than offset by $3.03 of acquired IPR&#38;D charges from Q2 business development activity, resulting in an updated range of $35.50 to $36.50.  </font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Regulatory progress included U.S. FDA approval of Ebglyss for one maintenance dose every eight weeks in moderate-to-severe atopic dermatitis, European Commission approval of Jaypirca as monotherapy for adults with chronic lymphocytic leukemia across all lines of therapy, and the submission for orforglipron for type 2 diabetes in the U.S.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Pipeline highlights included positive data from three additional Phase 3 trials of retatrutide in obesity. The clinical data package is now complete to support global registrations for obesity, obstructive sleep apnea, and knee osteoarthritis pain, with plans to submit a Biologics License Application to the U.S. FDA in the first quarter of 2027.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Business development activity in Q2 2026 included the completed acquisitions of Orna Therapeutics, Inc., Ajax Therapeutics, Inc., Centessa Pharmaceuticals plc. and Kelonia Therapeutics, Inc. Subsequent to quarter end, we completed three acquisitions to build an infectious disease portfolio and entered into an agreement to acquire AtaiBeckley, Inc.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Committed an additional $4.5 billion to expand Indiana manufacturing sites.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:180%">INDIANAPOLIS, August&#160;5, 2026 - Eli Lilly and Company (NYSE&#58; LLY) today announced its financial results for the second quarter of 2026 and provided updated 2026 financial guidance.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#34;Lilly's momentum continues, as we delivered 48% revenue growth and raised our full-year guidance,&#34; said David A. Ricks, Lilly chair and CEO. &#34;At the same time, Lilly is building for the future. With our next-generation weight-loss medicine retatrutide and its complete clinical data package in hand, new manufacturing capacity coming online, and exciting new assets entering our pipeline through business development, Lilly's future, after 150 years, has never been brighter.&#34;</font></div><div><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Eli Lilly and Company</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> &#124; Lilly Corporate Center &#124; Indianapolis, Indiana 46285 &#124; U.S.A.</font></div></div></div><div id="id7ff9e57898d493f8c8538147afd934e_4"></div><hr style="page-break-after:always"><div style="min-height:103.68pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Financial Results</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.705%"><tr><td style="width:1.0%"></td><td style="width:50.666%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.797%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.670%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.797%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.670%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.800%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$ in millions, except <br>per share data</font></td><td colspan="15" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Second-Quarter</font></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">2026</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">2025</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">% Change</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</font></td><td style="padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,974&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,558&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income &#8211; Reported</font></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,095&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,661&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings per share &#8211; Reported</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</font></div></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.94&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.29&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income &#8211; Non-GAAP</font></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,493&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,680&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings per share &#8211; Non-GAAP</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</font></div></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.38&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.31&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="18" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> Q2 2026 reported and non-GAAP EPS included $3.03 of acquired IPR&#38;D charges compared to $0.14 in Q2 2025</font></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:5pt"><font><br></font></div><div style="margin-top:5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:180%">A discussion of the non-GAAP financial measures is included below under &#34;Reconciliation of GAAP Reported to Selected Non-GAAP Adjusted Information (Unaudited).&#34;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:180%;text-decoration:underline">Second-Quarter Reported Results</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:180%">In Q2 2026, worldwide revenue was $23.0 billion, an increase of 48% compared with Q2 2025, driven by a 60% increase in volume, partially offset by a 13% decrease in realized prices. Key Products</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:180%;position:relative;top:-3.5pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:180%"> revenue grew to $15.7 billion in Q2 2026, led by Mounjaro and Zepbound. Key Products revenue in the Immunology, Oncology, and Neuroscience therapeutic areas grew 121% in Q2 2026 compared to Q2 2025.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:180%">Revenue in the U.S. increased 33% to $14.4 billion, driven by a 37% increase in volume, partially offset by a 3% decrease in realized prices. The increase in U.S. volume was driven by Zepbound and Mounjaro. </font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:180%">The decline in realized prices was primarily driven by Zepbound and Mounjaro, partially offset by adjustments to estimates for rebates and discounts primarily driven by Trulicity, Zepbound, and Mounjaro. Excluding these adjustments, U.S. price would have declined by approximately 9%. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:180%">Revenue outside the U.S. increased 80% to $8.6 billion, driven by a 113% increase in volume, partially offset by a 36% decrease in realized prices. The lower realized prices outside the U.S. were driven primarily by the addition of Mounjaro to the National Reimbursement Drug List (NRDL) in China. The </font></div><div style="border-bottom:1pt solid #000000;margin-bottom:5pt;margin-top:10pt;opacity:1;width:150pt"></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:112%;position:relative;top:-2.8pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%"> The Company currently defines Key Products as Ebglyss, Foundayo (added Q2 2026), Inluriyo, Jaypirca, Kisunla, Mounjaro, Omvoh, and Zepbound. </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#212121;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:180%">2</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:103.68pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:180%">volume increase outside the U.S. was driven by Mounjaro. Jardiance revenue outside the U.S. included a sales-based milestone of $250 million in Q2 2026, associated with the company's collaboration with Boehringer Ingelheim. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:180%">Gross margin increased 50% to $19.7 billion in Q2 2026. Gross margin as a percent of revenue was 85.8%, an increase of 1.5 percentage points versus the same quarter last year. The increase was primarily driven by improved cost of production and favorable product mix, partially offset by lower realized prices.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:180%">In Q2 2026, research and development expenses increased 14% to $3.8 billion, or 17% of revenue, driven by continued investments in the company's early and late-stage portfolio.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:180%">Marketing, selling, and administrative expenses increased 25% to $3.4 billion in Q2 2026, primarily driven by promotional efforts supporting ongoing and planned launches.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:180%">In Q2 2026, the company recognized acquired in-process research and development (IPR&#38;D) charges of </font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:180%">$2.8 billion compared with $154 million in Q2 2025. The Q2 2026 charges primarily related to the acquisitions of Orna Therapeutics, Inc. and Ajax Therapeutics, Inc.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:180%">Asset impairment, restructuring and other special charges of $703 million in Q2 2026 were primarily related to the accelerated vesting of employee equity awards and other acquisition and integration costs associated with the closing of our acquisitions of Kelonia Therapeutics, Inc. and Centessa Pharmaceuticals plc. In Q2 2025, there were no asset impairment, restructuring and other special charges. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:180%">The effective tax rate was 23.3% in Q2 2026 compared with 16.5% in Q2 2025, primarily driven by the unfavorable tax impact of non-deductible acquired IPR&#38;D charges in Q2 2026.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:180%">In Q2 2026, net income and earnings per share (EPS) were $7.1&#160;billion and $7.94, respectively, compared with net income of $5.7&#160;billion and EPS of $6.29 in Q2 2025. EPS in Q2 2026 and Q2 2025 included acquired IPR&#38;D charges of $3.03 and $0.14, respectively.</font></div><div><font><br></font></div><div id="id7ff9e57898d493f8c8538147afd934e_7"></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:180%;text-decoration:underline">Second-Quarter Non-GAAP Measures</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:180%">On a non-GAAP basis, Q2 2026 gross margin increased 50% to $19.8 billion. Gross margin as a percent of revenue was 86.3%, an increase of 1.3 percentage points versus the same quarter last year. The </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3</font></div></td></tr></table></div><div style="padding-left:36pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:103.68pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:180%">increase was primarily driven by improved cost of production and favorable product mix, partially offset by lower realized prices.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:180%">The non-GAAP effective tax rate was 22.2% in Q2 2026 compared with 16.5% in Q2 2025, primarily driven by the unfavorable tax impact of non-deductible acquired IPR&#38;D charges in Q2 2026.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:180%">On a non-GAAP basis, Q2 2026 net income and EPS were $7.5 billion and $8.38, respectively, compared with net income of $5.7&#160;billion and EPS of $6.31 in Q2 2025. Non-GAAP EPS in Q2 2026 and Q2 2025 included acquired IPR&#38;D charges of $3.03 and $0.14, respectively.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:180%">For further detail on non-GAAP measures, see the reconciliation below as well as the &#34;Reconciliation of GAAP Reported to Selected Non-GAAP Adjusted Information (Unaudited)&#34; table later in this press release.</font></div><div><font><br></font></div><div style="padding-left:9pt;text-indent:-9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.705%"><tr><td style="width:1.0%"></td><td style="width:50.666%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.797%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.670%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.797%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.670%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.800%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Second-Quarter</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">2026</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">2025</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">% Change</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Earnings per share (reported)</font></td><td style="padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7.94</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6.29</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">26%</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of intangible assets</font></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.11&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.11&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset impairment, restructuring and other special charges</font></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.72&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net gains on investments in equity securities</font></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(.39)</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(.09)</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Earnings per share (non-GAAP)</font></td><td style="border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8.38</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6.31</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">33%</font></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired IPR&#38;D</font></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.03&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.14&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NM</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Numbers may not add due to rounding</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="18" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">NM - not meaningful</font></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="padding-right:-18pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4</font></div></td></tr></table></div></div></div><div id="id7ff9e57898d493f8c8538147afd934e_10"></div><hr style="page-break-after:always"><div style="min-height:103.68pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selected Revenue Highlights</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.673%"><tr><td style="width:1.0%"></td><td style="width:19.670%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.127%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.972%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.127%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.972%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.127%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.972%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.127%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.972%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.127%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.972%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.135%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:18pt"><td colspan="6" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:180%">(Dollars in millions)</font></div></td><td colspan="15" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:180%;text-decoration:underline">Second-Quarter</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-right:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:180%;text-decoration:underline">Year-to-Date</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Selected Products</font></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">2026</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">2025</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">% Change</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">2026</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">2025</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">% Change</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2.62pt 1pt 1.5pt 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mounjaro</font></td><td style="padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,943&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,199&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91%</font></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,605&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,041&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Zepbound</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</font></div></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,928&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,381&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,088&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,693&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jaypirca</font></div></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">192&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">357&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ebglyss</font></div></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">346&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kisunla</font></div></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NM</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">291&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NM</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Omvoh</font></div></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inluriyo</font></div></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NM</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NM</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2.62pt 1pt 1.5pt 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foundayo</font></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NM</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NM</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:5pt"><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Revenue</font></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,974&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,558&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,773&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,286&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:5pt"><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-right:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="36" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Tirzepatide is marketed for obesity under the brand name Zepbound in Canada, Japan, and the United States.</font></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="36" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">NM - not meaningful</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td></tr></table></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:180%;text-decoration:underline">Mounjaro</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:180%">For Q2 2026, worldwide Mounjaro revenue increased 91% to $9.9 billion. U.S. revenue was $4.8 billion, an increase of 45%, reflecting strong demand, partially offset by lower realized prices. Lower realized prices were partially offset by adjustments to estimates for rebates and discounts. Revenue outside the U.S. increased 172% to $5.2 billion primarily driven by volume growth, partially offset by lower realized prices driven by the addition of Mounjaro to the NRDL in Q1 2026.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:180%;text-decoration:underline">Zepbound</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:180%">For Q2 2026, U.S. Zepbound revenue increased 44% to $4.9 billion, primarily driven by strong demand, partially offset by lower realized prices, including previously announced reductions in cash-pay prices. Lower realized prices were partially offset by adjustments to estimates for rebates and discounts.</font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="padding-right:-18pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5</font></div></td></tr></table></div></div></div><div id="id7ff9e57898d493f8c8538147afd934e_13"></div><hr style="page-break-after:always"><div style="min-height:103.68pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:180%">Lilly shared numerous updates recently on key regulatory, clinical, business development, and other events, including&#58;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.771%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:79.029%"></td><td style="width:0.1%"></td></tr><tr style="height:35pt"><td colspan="3" rowspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Regulatory</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lilly's Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union for adults with chronic lymphocytic leukemia (CLL) across all lines of therapy (announcement)</font></td></tr><tr style="height:35pt"><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">FDA approves Lilly's EBGLYSS&#174; (lebrikizumab-lbkz) for one maintenance dose every eight weeks in patients with moderate-to-severe atopic dermatitis (announcement)</font></td></tr><tr style="height:35pt"><td colspan="3" rowspan="11" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lilly's olomorasib receives U.S. FDA's Breakthrough Therapy designation for the treatment of previously treated KRAS G12C-mutant advanced pancreatic cancer (announcement)</font></td></tr><tr style="height:24pt"><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1C (announcement)</font></td></tr><tr style="height:35pt"><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lilly's Jaypirca (pirtobrutinib) significantly reduced the risk of disease progression or death by 45% when added to a venetoclax time-limited regimen in people with previously treated CLL&#47;SLL (announcement)</font></td></tr><tr style="height:35pt"><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lilly's oral GLP-1 Foundayo (orforglipron) delivered superior A1C control and weight loss in three pivotal type 2 diabetes trials (announcement)</font></td></tr><tr style="height:36pt"><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lilly's Foundayo (orforglipron), the only oral GLP-1 taken without food or water restrictions, was associated with significant weight loss in women at every stage of menopause (announcement)</font></td></tr><tr style="height:35pt"><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lilly's triple agonist, retatrutide, drove substantial improvements in weight, A1C, knee osteoarthritis pain, and obstructive sleep apnea, demonstrating its remarkable potential to treat obesity and its complications (announcement)</font></td></tr><tr style="height:35pt"><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lilly's Retevmo (selpercatinib) demonstrated an 83% reduction in the risk of disease recurrence or death as adjuvant therapy for people with early-stage RET fusion-positive lung cancer (announcement)</font></td></tr><tr style="height:35pt"><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">A single dose of Lilly's PCSK9 base editor, VERVE-102, reduced PCSK9 by up to 88% and LDL-C by up to 62%, with durable effects supporting its potential as a one-time treatment for hypercholesterolemia (announcement)</font></td></tr><tr style="height:24pt"><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial (announcement)</font></td></tr><tr style="height:35pt"><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lilly's Foundayo and lower-dose Zepbound helped people maintain weight loss after switching from higher doses of injectable incretin therapy in two late-phase trials (announcement)</font></td></tr><tr style="height:24pt"><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lilly's Omvoh (mirikizumab-mrkz) is the first and only IL-23p19 to demonstrate durable disease clearance in ulcerative colitis through four years (announcement)</font></td></tr><tr style="height:27pt"><td colspan="3" rowspan="7" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lilly to acquire AtaiBeckley to advance therapies for treatment-resistant depression and other mental health conditions (announcement)</font></td></tr><tr style="height:27pt"><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">What Medicare Part D patients need to know about accessing Foundayo (orforglipron) and Zepbound (tirzepatide) for weight management (announcement)</font></td></tr><tr style="height:24pt"><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lilly completes acquisition of Centessa Pharmaceuticals to advance treatments for sleep-wake disorders (announcement)</font></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foundayo and Zepbound now covered for millions of Americans (announcement)</font></td></tr><tr style="height:24pt"><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lilly announces three acquisitions to build infectious disease portfolio (announcement)</font></td></tr><tr><td colspan="3" style="display:none"></td></tr><tr style="height:24pt"><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lilly commits additional $4.5 billion across Indiana manufacturing sites, opens first dedicated genetic medicine facility (announcement)</font></td></tr></table></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:180%">For information on important public announcements, visit the news section of Lilly's website.</font></div><div><font><br></font></div><div id="id7ff9e57898d493f8c8538147afd934e_16"></div><div style="margin-top:5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:180%;text-decoration:underline">2026 Financial Guidance </font></div><div style="margin-top:5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:180%">In addition to providing guidance for GAAP revenue, Lilly provides guidance for certain non-GAAP measures.</font></div><div style="margin-top:5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:180%">The following table summarizes the company's updated full-year 2026 non-GAAP financial guidance, reflecting the continued strong revenue performance in Q2. The first half of 2026 also benefited from sales based milestones and adjustments for rebates and discounts. In addition to updates to Revenue and Performance Margin guidance, EPS guidance has been adjusted to reflect an increase of $2.78 (at the midpoint of the range) due to strong underlying business growth, offset by $3.03 associated with the Q2 acquired IPR&#38;D charges from recent business development activity&#58; </font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.955%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.417%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.140%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.822%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Prior</font></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Updated</font></td></tr><tr style="height:14pt"><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$82 to $85 billion</font></td><td colspan="3" style="border-right:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$85 to $87 billion</font></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance Margin</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)(2)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.0% to 48.5%</font></td><td colspan="3" style="border-right:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.0% to 50.5%</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax Rate</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)(3)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18% to 19%</font></td><td colspan="3" style="border-right:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">unchanged</font></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings per Share</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)(3)(4)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$35.50 to $37.00</font></td><td colspan="3" style="border-right:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$35.50 to $36.50</font></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td></tr><tr><td colspan="15" style="border-left:1pt solid #000;border-right:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> Lilly does not provide reconciliations of forward-looking non-GAAP measures to the most directly comparable GAAP measures because comparable GAAP measures are not reasonably accessible or reliable due to the inherent difficulty in forecasting and quantifying measures that would be necessary for a reconciliation. In particular, Lilly cannot reasonably predict certain items including net gains and losses on equity securities, asset impairment, acquisition or divestiture-related items, or restructuring and other adjustments, without unreasonable effort. These items are uncertain, depend on various factors, and could have a material impact on Lilly's reported results in accordance with GAAP. See Reconciliation of GAAP Reported to Selected Non-GAAP Adjusted Information (Unaudited) table below for additional Non-GAAP information.</font></div></td></tr><tr><td colspan="15" style="border-left:1pt solid #000;border-right:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> The company defines performance margin as gross margin less research and development and marketing, selling, and administrative expenses divided by revenue. </font></div></td></tr><tr><td colspan="15" style="border-left:1pt solid #000;border-right:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> Guidance does not include acquired in-process research and development (IPR&#38;D) incurred after June 30, 2026. </font></div></td></tr><tr><td colspan="15" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> Assumes shares outstanding of approximately 894 million and foreign currency exchange rate assumptions of 1.14 (Euro), 153 (Yen) and 7.1 (Yuan)</font></div></td></tr><tr><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="padding-right:-18pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:103.68pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div></div><div style="margin-top:5pt"><font><br></font></div><div id="id7ff9e57898d493f8c8538147afd934e_19"></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:180%">Webcast of Conference Call</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:180%">As previously announced, investors and the general public can access a live webcast of the Q2 2026 financial results conference call through a link on Lilly's website at investor.lilly.com&#47;webcasts-and-presentations. The conference call will begin at 10 a.m. Eastern time today and will be available for replay via the website.</font></div><div><font><br></font></div><div style="margin-top:5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:180%">Non-GAAP Financial Measures</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:180%">Certain financial information is presented on both a reported and a non-GAAP basis. Some numbers in this press release may not add due to rounding. Reported results were prepared in accordance with U.S. generally accepted accounting principles (GAAP) and include all revenue and expenses recognized during the periods. Historical non-GAAP measures reflect adjustments for the items described in the reconciliation tables later in the release. Related materials provide certain GAAP and non-GAAP figures excluding the impact of foreign exchange rates. Lilly recalculates current period figures on a constant currency basis by keeping constant the exchange rates from the base period. The company's 2026 financial guidance (other than revenue) is provided on a non-GAAP basis, as described in &#34;2026 Financial Guidance&#34; above. Non-GAAP measures are presented to provide additional insights into the underlying trends in the company's business.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:180%">About Lilly</font></div><div><font style="background-color:#ffffff;color:#212121;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:180%">Lilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges&#58; redefining diabetes care&#59; treating obesity and curtailing its most devastating long-term effects&#59; advancing the fight against Alzheimer's disease&#59; providing solutions to some of the most debilitating immune system disorders&#59; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing&#58; making life better for millions more people. That includes delivering innovative clinical trials</font><font style="color:#212121;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:180%"> that reflect the diversity of our world and working to en</font><font style="background-color:#ffffff;color:#212121;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:180%">sure our medicines are accessible and affordable. To learn more, visit Lilly.com and Lilly.com&#47;news. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:180%">F-LLY</font></div><div><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="padding-right:-18pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:103.68pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:180%">Cautionary Statement Regarding Forward-Looking Statements</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">This press release and the related attachments contain management's intentions and expectations for the future, all of which are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. The words &#34;estimate&#34;, &#34;project&#34;, &#34;intend&#34;, &#34;expect&#34;, &#34;believe&#34;, &#34;target&#34;, &#34;plan&#34;, &#34;anticipate&#34;, &#34;may&#34;, &#34;could&#34;, &#34;aim&#34;, &#34;seek&#34;, &#34;will&#34;, &#34;continue&#34;, and similar expressions are intended to identify forward-looking statements. Actual results may differ materially due to various factors. The following include some but not all of the factors that could cause actual results or events to differ from those anticipated, including the significant costs and uncertainties in the pharmaceutical research and development process, including with respect to the timing and process of obtaining regulatory approvals and the ability of the company's clinical trials to meet expectations&#59; the impact and uncertain outcome of acquisitions and business development transactions and related costs&#59; intense competition affecting the company's products, pipeline, or industry&#59; market uptake of launched products and indications&#59; continued pricing pressures and the impact of actions of governmental and private actors affecting pricing of, reimbursement for, and patient access to pharmaceuticals, or reporting obligations related thereto&#59; the implementation of the company's voluntary agreement with the U.S. government related to drug pricing and access&#59; developments or uncertainties related to the company's or competitive products, including as may relate to safety or efficacy concerns&#59; dependence on relatively few products or product classes for a significant percentage of the company's total revenue and a consolidated supply chain&#59; the expiration of intellectual property protection for certain of the company's products and competition from generic and biosimilar products&#59; the company's ability to protect and enforce patents and other intellectual property and changes in patent law or regulations related to data package exclusivity&#59; information technology system inadequacies, inadequate controls or procedures, security breaches, or operating failures&#59; unauthorized access, disclosure, misappropriation, or compromise of confidential information or other data stored in the company's information technology systems, networks, and facilities, or those of third parties with whom the company shares its data and violations of data protection laws or regulations&#59; issues with product supply, regulatory approvals, or other negative outcomes stemming from manufacturing difficulties, disruptions, or shortages, including as a result of unpredictability and variability in demand, labor shortages, third-party performance, quality, cyber-attacks, or regulatory actions related to the company's and third-party facilities&#59; reliance on third-party relationships and outsourcing arrangements&#59; the use of artificial intelligence or other emerging technologies in various facets of the company's operations, including partnerships related to the use of, or the sharing of such technologies with third parties, which may exacerbate competitive, regulatory, litigation, cybersecurity, and other risks&#59; the impact of global macroeconomic conditions, including uneven economic growth or downturns or uncertainty, trade and other global disputes and interruptions, including related to tariffs, trade protection measures, and similar restrictions, international tension, conflicts, regional dependencies, or other costs, uncertainties, and risks related to engaging in business globally&#59; fluctuations in foreign currency exchange rates, changes in interest rates and inflation or deflation&#59; significant and sudden declines or volatility in the trading price of the company's common stock and market capitalization&#59; litigation, investigations, or other similar proceedings involving past, current, or future products, activities, or intellectual property&#59; changes in tax law and regulations, tax rates, or events that differ from the company's assumptions related to tax positions&#59; regulatory changes, developments, and uncertainty&#59; regulatory oversight and actions regarding the company's operations and products&#59; regulatory compliance problems or government investigations&#59; risks from the proliferation of counterfeit, misbranded, adulterated, or illegally compounded products&#59; actual or perceived deviation from environmental-, social-, or governance-related requirements or expectations&#59; asset impairments and restructuring charges&#59; and changes in accounting and reporting standards. For additional information about the factors that could cause actual results or events to differ materially from forward-looking statements, please see the company's latest Form 10-K and subsequent Forms 8-K and 10-Q filed with the Securities and Exchange Commission. You should not place undue reliance on forward-looking statements contained in this press release and the related attachments, which, except as otherwise noted, speak only as of the date of this release. Except as is required by law, the company expressly disclaims any obligation to publicly release any revisions to forward-looking statements contained in this press release and the related attachments to reflect events or circumstances after the date of this release.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;#&#160;&#160;&#160;&#160;#&#160;&#160;&#160;&#160;#</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Website Information</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The information contained on, or that may be accessed through, our website or any third-party website is not incorporated by reference into, and is not a part of, this earnings release.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Trademarks and Trade Names</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">All trademarks or trade names referred to in this press release are the property of the company, or, to the extent trademarks or trade names belonging to other companies are referenced in this press release, the property of their respective owners. Solely for convenience, the trademarks and trade names in this press release are referred to without the &#174; and &#8482; symbols, but such references should not be construed as any indicator that the company or, to the extent applicable, their respective owners will not assert, to the fullest extent under applicable law, the company's or their rights thereto. We do not intend the use or display of other companies&#8217; trademarks and trade names to imply a relationship with, or endorsement or sponsorship of us by, any other companies.</font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="padding-right:-18pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8</font></div></td></tr></table></div></div></div><div id="id7ff9e57898d493f8c8538147afd934e_22"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly and Company</font></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating Results (Unaudited) &#8211; REPORTED</font></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Dollars in millions, except per share data&#59; numbers may not add due to rounding)</font></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.502%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.700%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.700%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.700%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.262%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.700%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.700%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.700%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.681%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Six Months Ended</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2026</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">% Chg.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2026</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">% Chg.</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue</font></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22,974&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,558&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">48%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42,773&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28,286&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">51%</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost of sales</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,268&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,448&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,845&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,672&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">47%</font></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,819&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,336&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,329&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,070&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21%</font></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketing, selling, and administrative</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,430&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,753&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,364&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,221&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22%</font></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acquired IPR&#38;D</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,776&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">154&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">NM</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,360&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,726&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">95%</font></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset impairment, restructuring and other special charges</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">703&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">NM</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">982&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">NM</font></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 10pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating income</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,978&#160;</font></td><td style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,867&#160;</font></td><td style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,893&#160;</font></td><td style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,562&#160;</font></td><td style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">69%</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 10pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net interest income (expense)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(274)</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(209)</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(527)</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(405)</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 10pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net other income (expense)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">543&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">119&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">731&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">76&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other income (expense)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">269&#160;</font></td><td style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(90)</font></td><td style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">NM</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">204&#160;</font></td><td style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(329)</font></td><td style="border-top:1pt solid #000000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(162)%</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income before income taxes</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,247&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,777&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">36%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18,097&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,233&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">77%</font></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax expense</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,152&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,116&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">93%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,606&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,813&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">99%</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income</font></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,095&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,661&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,491&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,420&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">72%</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Earnings per share - diluted</font></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.94&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.29&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16.19&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.35&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">73%</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividends paid per share</font></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.73&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.50&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.46&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.00&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15%</font></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average shares outstanding (thousand) - diluted</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">893,671&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">899,793&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">894,837&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">900,199&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">NM &#8211; not meaningful</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="padding-right:-18pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9</font></div></td></tr></table></div></div></div><div id="id7ff9e57898d493f8c8538147afd934e_25"></div><hr style="page-break-after:always"><div style="min-height:117pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.433%"><tr><td style="width:1.0%"></td><td style="width:39.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.103%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.052%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.052%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.103%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.052%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.056%"></td><td style="width:0.1%"></td></tr><tr><td colspan="21" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Eli Lilly and Company</font></td></tr><tr><td colspan="21" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reconciliation of GAAP Reported to Selected Non-GAAP Adjusted Information (Unaudited)</font></td></tr><tr><td colspan="21" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in millions, except per share data&#59; numbers may not add due to rounding)</font></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended June 30,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Six Months Ended June 30,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2026</font></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2026</font></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</font></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Margin - As Reported</font></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">19,706</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td style="border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">13,110</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">35,928</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td style="border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">23,614</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Increase for excluded items&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of intangible assets (Cost of sales)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">125&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">122&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">253&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">245&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross Margin - Non-GAAP</font></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19,831&#160;</font></td><td style="border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td style="border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,232&#160;</font></td><td style="border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">36,181&#160;</font></td><td style="border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td style="border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23,859&#160;</font></td><td style="border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Margin as a percent of revenue - As Reported</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">85.8</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">84.3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">84.0</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">83.5</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross Margin as a percent of revenue - Non-GAAP</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">86.3&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">85.0&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">84.6&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">84.3&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</font></td></tr></table></div><div style="margin-bottom:3pt;margin-top:3pt"><font><br></font></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.34pt">Excludes amortization of intangibles primarily associated with costs of marketed products acquired or licensed from third parties.</font></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2.     Non-GAAP gross margin as a percent of revenue reflects the gross margin effects of the adjustments presented above.</font></div><div style="margin-bottom:3pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="padding-right:-18pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:117pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.949%"><tr><td style="width:1.0%"></td><td style="width:38.502%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.065%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.366%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.366%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.065%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.366%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.370%"></td><td style="width:0.1%"></td></tr><tr><td colspan="21" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reconciliation of GAAP Reported to Selected Non-GAAP Adjusted Information (Unaudited)</font></td></tr><tr><td colspan="21" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in millions, except per share data&#59; numbers may not add due to rounding)</font></td></tr><tr style="height:12pt"><td colspan="21" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended June 30,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Six Months Ended June 30,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2026</font></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2026</font></td><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</font></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net income - Reported</font></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">7,095</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td style="border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5,661</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">14,491</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td style="border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">8,420</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Increase (decrease) for excluded items&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of intangible assets (Cost of sales)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">125&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">122&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">253&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">245&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset impairment, restructuring and other special charges</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">703&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">982&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 10pt;text-align:left;text-indent:-0.01pt;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net (gains) losses on investments in equity securities (Other income&#47;expense)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(445)</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(99)</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(524)</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">53&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 10pt;text-align:left;text-indent:-0.01pt;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corresponding tax effects (Income taxes)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4)</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(46)</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(69)</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income - Non-GAAP</font></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,493&#160;</font></td><td style="border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td style="border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,680&#160;</font></td><td style="border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,156&#160;</font></td><td style="border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td style="border-top:1pt solid #000;padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,684&#160;</font></td><td style="border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effective tax rate - Reported</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">23.3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">16.5</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">19.9</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">17.7</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Effective tax rate - Non-GAAP</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22.2&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16.5&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19.4&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="padding:2.62pt 0 1.5pt 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17.8&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Earnings per share (diluted) - Reported</font></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</font></td><td style="padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">7.94</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td style="padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</font></td><td style="padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">6.29</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</font></td><td style="padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">16.19</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td style="padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</font></td><td style="padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">9.35</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Earnings per share (diluted) - Non-GAAP</font></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.38&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td style="padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.31&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16.94&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td><td style="padding:2.62pt 0 1.5pt 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2.62pt 0 1.5pt 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.65&#160;</font></td><td style="padding:2.62pt 1pt 1.5pt 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:3pt"><font><br></font></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.34pt">Excludes amortization of intangibles primarily associated with costs of marketed products acquired or licensed from third parties. </font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">2.  </font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">   </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">For the three months ended June&#160;30, 2026, excluded charges primarily related to the accelerated vesting of employee equity awards and other acquisition and integration costs associated with the closing of the company's acquisitions of Kelonia Therapeutics, Inc. and Centessa Pharmaceuticals plc. For the six months ended June 30, 2026, also excluded charges related to litigation matters. </font></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">3.     Non-GAAP tax rate reflects the tax effects of the adjustments presented above.</font></div><div style="margin-bottom:3pt;padding-left:36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2.62pt 1pt 1.5pt 1pt;text-align:left;vertical-align:middle"><div style="padding-right:-18pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11</font></div></td></tr></table></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>lly-20260805.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:019f8a77-cc87-70d8-bcd7-b8b7964653b4,g:c8da2307-0382-494c-ac1c-f110104979d9-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:lly="http://www.lilly.com/20260805" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2024-01-31" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.lilly.com/20260805">
  <xs:import namespace="http://fasb.org/us-gaap/2026" schemaLocation="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2024-01-31" schemaLocation="https://www.xbrl.org/dtr/type/2024-01-31/types.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2026" schemaLocation="https://xbrl.sec.gov/dei/2026/dei-2026.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lly-20260805_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lly-20260805_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lly-20260805_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.lilly.com/role/CoverPage">
        <link:definition>0000001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="lly_A2.125NotesDueJune32030Member" abstract="true" name="A2.125NotesDueJune32030Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_A625Notesdue2031Member" abstract="true" name="A625Notesdue2031Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_A6.77NotesDueJanuary12036Member" abstract="true" name="A6.77NotesDueJanuary12036Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_A1.700Notesdue2049Member" abstract="true" name="A1.700Notesdue2049Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_A500NotesDue2033Member" abstract="true" name="A500NotesDue2033Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_A1625NotesDue2043Member" abstract="true" name="A1625NotesDue2043Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_A1125NotesDue2051Member" abstract="true" name="A1125NotesDue2051Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_A1375NotesDue2061Member" abstract="true" name="A1375NotesDue2061Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>4
<FILENAME>lly-20260805_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:019f8a77-cc87-70d8-bcd7-b8b7964653b4,g:c8da2307-0382-494c-ac1c-f110104979d9-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.lilly.com/role/CoverPage" xlink:type="simple" xlink:href="lly-20260805.xsd#CoverPage"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems_019f8a77-cc87-7617-9ba8-94b1e0cd9892" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable_019f8a77-cc87-7983-9105-d26e767514ae" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentInformationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_DocumentInformationLineItems_019f8a77-cc87-7617-9ba8-94b1e0cd9892" xlink:to="loc_dei_DocumentInformationTable_019f8a77-cc87-7983-9105-d26e767514ae" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_019f8a77-cc87-7555-9c16-3748ceb8b93a" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_DocumentInformationTable_019f8a77-cc87-7983-9105-d26e767514ae" xlink:to="loc_us-gaap_StatementClassOfStockAxis_019f8a77-cc87-7555-9c16-3748ceb8b93a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_019f8a77-cc87-7555-9c16-3748ceb8b93a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_019f8a77-cc87-7555-9c16-3748ceb8b93a" xlink:to="loc_us-gaap_ClassOfStockDomain_019f8a77-cc87-7555-9c16-3748ceb8b93a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_019f8a77-cc87-7da8-80fb-c5f57f0653ba" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_019f8a77-cc87-7555-9c16-3748ceb8b93a" xlink:to="loc_us-gaap_ClassOfStockDomain_019f8a77-cc87-7da8-80fb-c5f57f0653ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_019f8a77-cc87-7a06-bd2d-5ad0091e1632" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_019f8a77-cc87-7da8-80fb-c5f57f0653ba" xlink:to="loc_us-gaap_CommonClassAMember_019f8a77-cc87-7a06-bd2d-5ad0091e1632" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A2.125NotesDueJune32030Member_019f8a77-cc87-7f4a-bf35-4ef66bf9d2ca" xlink:href="lly-20260805.xsd#lly_A2.125NotesDueJune32030Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_019f8a77-cc87-7da8-80fb-c5f57f0653ba" xlink:to="loc_lly_A2.125NotesDueJune32030Member_019f8a77-cc87-7f4a-bf35-4ef66bf9d2ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A625Notesdue2031Member_019f8a77-cc87-794f-9a4f-11e51952a398" xlink:href="lly-20260805.xsd#lly_A625Notesdue2031Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_019f8a77-cc87-7da8-80fb-c5f57f0653ba" xlink:to="loc_lly_A625Notesdue2031Member_019f8a77-cc87-794f-9a4f-11e51952a398" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A6.77NotesDueJanuary12036Member_019f8a77-cc87-749f-8a65-96a3a388c7bf" xlink:href="lly-20260805.xsd#lly_A6.77NotesDueJanuary12036Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_019f8a77-cc87-7da8-80fb-c5f57f0653ba" xlink:to="loc_lly_A6.77NotesDueJanuary12036Member_019f8a77-cc87-749f-8a65-96a3a388c7bf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1.700Notesdue2049Member_019f8a77-cc87-7397-8424-333c9e6acc59" xlink:href="lly-20260805.xsd#lly_A1.700Notesdue2049Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_019f8a77-cc87-7da8-80fb-c5f57f0653ba" xlink:to="loc_lly_A1.700Notesdue2049Member_019f8a77-cc87-7397-8424-333c9e6acc59" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A500NotesDue2033Member_019f8a77-cc87-7bbd-878f-d31e693825e8" xlink:href="lly-20260805.xsd#lly_A500NotesDue2033Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_019f8a77-cc87-7da8-80fb-c5f57f0653ba" xlink:to="loc_lly_A500NotesDue2033Member_019f8a77-cc87-7bbd-878f-d31e693825e8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1625NotesDue2043Member_019f8a77-cc87-7bff-8b0c-cf802b927ce1" xlink:href="lly-20260805.xsd#lly_A1625NotesDue2043Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_019f8a77-cc87-7da8-80fb-c5f57f0653ba" xlink:to="loc_lly_A1625NotesDue2043Member_019f8a77-cc87-7bff-8b0c-cf802b927ce1" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1125NotesDue2051Member_019f8a77-cc87-7128-baa1-dff99fa1ca14" xlink:href="lly-20260805.xsd#lly_A1125NotesDue2051Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_019f8a77-cc87-7da8-80fb-c5f57f0653ba" xlink:to="loc_lly_A1125NotesDue2051Member_019f8a77-cc87-7128-baa1-dff99fa1ca14" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1375NotesDue2061Member_019f8a77-cc87-7f74-87da-2885adb880dc" xlink:href="lly-20260805.xsd#lly_A1375NotesDue2061Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_019f8a77-cc87-7da8-80fb-c5f57f0653ba" xlink:to="loc_lly_A1375NotesDue2061Member_019f8a77-cc87-7f74-87da-2885adb880dc" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_019f8a77-cc87-7d4b-9634-75d0791110bf" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentType"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_019f8a77-cc87-7617-9ba8-94b1e0cd9892" xlink:to="loc_dei_DocumentType_019f8a77-cc87-7d4b-9634-75d0791110bf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_019f8a77-cc87-72a6-83f9-f79c0a7d3582" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentPeriodEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_019f8a77-cc87-7617-9ba8-94b1e0cd9892" xlink:to="loc_dei_DocumentPeriodEndDate_019f8a77-cc87-72a6-83f9-f79c0a7d3582" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_019f8a77-cc87-7acd-8611-dbdb1aa389ba" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_019f8a77-cc87-7617-9ba8-94b1e0cd9892" xlink:to="loc_dei_EntityIncorporationStateCountryCode_019f8a77-cc87-7acd-8611-dbdb1aa389ba" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_019f8a77-cc87-7406-b7c4-dfd32bc57576" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityFileNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_019f8a77-cc87-7617-9ba8-94b1e0cd9892" xlink:to="loc_dei_EntityFileNumber_019f8a77-cc87-7406-b7c4-dfd32bc57576" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_019f8a77-cc87-7b07-9baf-0d58f56f474f" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_019f8a77-cc87-7617-9ba8-94b1e0cd9892" xlink:to="loc_dei_EntityTaxIdentificationNumber_019f8a77-cc87-7b07-9baf-0d58f56f474f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_019f8a77-cc87-7f12-bf25-04f227eaea73" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressAddressLine1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_019f8a77-cc87-7617-9ba8-94b1e0cd9892" xlink:to="loc_dei_EntityAddressAddressLine1_019f8a77-cc87-7f12-bf25-04f227eaea73" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_019f8a77-cc87-7e1e-917f-25e5f3293ba2" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressCityOrTown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_019f8a77-cc87-7617-9ba8-94b1e0cd9892" xlink:to="loc_dei_EntityAddressCityOrTown_019f8a77-cc87-7e1e-917f-25e5f3293ba2" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_019f8a77-cc87-7f9a-bcdd-3779e7d81594" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressStateOrProvince"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_019f8a77-cc87-7617-9ba8-94b1e0cd9892" xlink:to="loc_dei_EntityAddressStateOrProvince_019f8a77-cc87-7f9a-bcdd-3779e7d81594" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_019f8a77-cc87-7418-b018-4d5289019617" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressPostalZipCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_019f8a77-cc87-7617-9ba8-94b1e0cd9892" xlink:to="loc_dei_EntityAddressPostalZipCode_019f8a77-cc87-7418-b018-4d5289019617" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_019f8a77-cc87-7fa6-9083-57634c136bab" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_CityAreaCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_019f8a77-cc87-7617-9ba8-94b1e0cd9892" xlink:to="loc_dei_CityAreaCode_019f8a77-cc87-7fa6-9083-57634c136bab" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_019f8a77-cc87-7077-a851-23eca7e4196f" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_LocalPhoneNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_019f8a77-cc87-7617-9ba8-94b1e0cd9892" xlink:to="loc_dei_LocalPhoneNumber_019f8a77-cc87-7077-a851-23eca7e4196f" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_019f8a77-cc87-7657-a4de-d820e26d5b67" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_WrittenCommunications"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_019f8a77-cc87-7617-9ba8-94b1e0cd9892" xlink:to="loc_dei_WrittenCommunications_019f8a77-cc87-7657-a4de-d820e26d5b67" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_019f8a77-cc87-74da-9c0a-e0fe341d0387" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_SolicitingMaterial"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_019f8a77-cc87-7617-9ba8-94b1e0cd9892" xlink:to="loc_dei_SolicitingMaterial_019f8a77-cc87-74da-9c0a-e0fe341d0387" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_019f8a77-cc87-727a-bc2e-fd9a59cfbdcd" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_PreCommencementTenderOffer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_019f8a77-cc87-7617-9ba8-94b1e0cd9892" xlink:to="loc_dei_PreCommencementTenderOffer_019f8a77-cc87-727a-bc2e-fd9a59cfbdcd" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_019f8a77-cc87-7463-8136-8c2a7bdb08be" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_019f8a77-cc87-7617-9ba8-94b1e0cd9892" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_019f8a77-cc87-7463-8136-8c2a7bdb08be" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_019f8a77-cc87-7bdb-9d34-cf1ea95f5f4a" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_019f8a77-cc87-7617-9ba8-94b1e0cd9892" xlink:to="loc_dei_EntityEmergingGrowthCompany_019f8a77-cc87-7bdb-9d34-cf1ea95f5f4a" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_019f8a77-cc87-7a43-b726-ad4d57c800d0" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_Security12bTitle"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_019f8a77-cc87-7617-9ba8-94b1e0cd9892" xlink:to="loc_dei_Security12bTitle_019f8a77-cc87-7a43-b726-ad4d57c800d0" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_019f8a77-cc87-7ec9-9563-659968761435" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_TradingSymbol"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_019f8a77-cc87-7617-9ba8-94b1e0cd9892" xlink:to="loc_dei_TradingSymbol_019f8a77-cc87-7ec9-9563-659968761435" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_019f8a77-cc87-770f-a007-5a0c16c424f5" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_SecurityExchangeName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_019f8a77-cc87-7617-9ba8-94b1e0cd9892" xlink:to="loc_dei_SecurityExchangeName_019f8a77-cc87-770f-a007-5a0c16c424f5" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_019f8a77-cc87-7f39-a98e-ec0a2b89949a" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityRegistrantName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_019f8a77-cc87-7617-9ba8-94b1e0cd9892" xlink:to="loc_dei_EntityRegistrantName_019f8a77-cc87-7f39-a98e-ec0a2b89949a" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_019f8a77-cc87-750b-b460-914ba7fc0a11" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityCentralIndexKey"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_019f8a77-cc87-7617-9ba8-94b1e0cd9892" xlink:to="loc_dei_EntityCentralIndexKey_019f8a77-cc87-750b-b460-914ba7fc0a11" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_019f8a77-cc87-7cca-a6ae-0fb9c46dea56" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_AmendmentFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_019f8a77-cc87-7617-9ba8-94b1e0cd9892" xlink:to="loc_dei_AmendmentFlag_019f8a77-cc87-7cca-a6ae-0fb9c46dea56" xlink:type="arc" order="21"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>lly-20260805_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:019f8a77-cc87-70d8-bcd7-b8b7964653b4,g:c8da2307-0382-494c-ac1c-f110104979d9-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_EntityTaxIdentificationNumber_019f8a77-cc87-779d-8312-1376ebc23d3a_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_019f8a77-cc87-731f-aa4a-3b15bc717c54_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A1125NotesDue2051Member_019f8a77-cc87-754a-95dd-aeb7af08b6db_terseLabel_en-US" xlink:label="lab_lly_A1125NotesDue2051Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">1.125% Notes due 2051</link:label>
    <link:label id="lab_lly_A1125NotesDue2051Member_label_en-US" xlink:label="lab_lly_A1125NotesDue2051Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">1.125% Notes due 2051 [Member]</link:label>
    <link:label id="lab_lly_A1125NotesDue2051Member_documentation_en-US" xlink:label="lab_lly_A1125NotesDue2051Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">1.125% Notes due 2051</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1125NotesDue2051Member" xlink:href="lly-20260805.xsd#lly_A1125NotesDue2051Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A1125NotesDue2051Member" xlink:to="lab_lly_A1125NotesDue2051Member" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A1625NotesDue2043Member_019f8a77-cc87-7b25-a72f-d5ca27b99b59_terseLabel_en-US" xlink:label="lab_lly_A1625NotesDue2043Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">1.625%&#160;Notes due 2043</link:label>
    <link:label id="lab_lly_A1625NotesDue2043Member_label_en-US" xlink:label="lab_lly_A1625NotesDue2043Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">1.625%&#160;Notes due 2043 [Member]</link:label>
    <link:label id="lab_lly_A1625NotesDue2043Member_documentation_en-US" xlink:label="lab_lly_A1625NotesDue2043Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">1.625%&#160;Notes due 2043</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1625NotesDue2043Member" xlink:href="lly-20260805.xsd#lly_A1625NotesDue2043Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A1625NotesDue2043Member" xlink:to="lab_lly_A1625NotesDue2043Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_019f8a77-cc87-7f1e-bfd3-fe5d2e92c6dd_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_019f8a77-cc87-7328-8d2f-84f6baea4c2e_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A1.700Notesdue2049Member_019f8a77-cc87-7080-b707-e3254a09285c_terseLabel_en-US" xlink:label="lab_lly_A1.700Notesdue2049Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">1.700% Notes due 2049</link:label>
    <link:label id="lab_lly_A1.700Notesdue2049Member_label_en-US" xlink:label="lab_lly_A1.700Notesdue2049Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">1.700% Notes due 2049 [Member]</link:label>
    <link:label id="lab_lly_A1.700Notesdue2049Member_documentation_en-US" xlink:label="lab_lly_A1.700Notesdue2049Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">1.700% Notes due 2049 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1.700Notesdue2049Member" xlink:href="lly-20260805.xsd#lly_A1.700Notesdue2049Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A1.700Notesdue2049Member" xlink:to="lab_lly_A1.700Notesdue2049Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_019f8a77-cc87-768e-aefd-570bf3c8366f_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_019f8a77-cc87-71c1-a083-ce829fd28eb1_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_019f8a77-cc87-701c-bed4-1f2f77bed974_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_019f8a77-cc87-779a-8e53-0f61d8f87aa4_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A1375NotesDue2061Member_019f8a77-cc87-7440-87ad-56220782f6d6_terseLabel_en-US" xlink:label="lab_lly_A1375NotesDue2061Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">1.375% Notes due 2061</link:label>
    <link:label id="lab_lly_A1375NotesDue2061Member_label_en-US" xlink:label="lab_lly_A1375NotesDue2061Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">1.375% Notes due 2061 [Member]</link:label>
    <link:label id="lab_lly_A1375NotesDue2061Member_documentation_en-US" xlink:label="lab_lly_A1375NotesDue2061Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">1.375% Notes due 2061</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1375NotesDue2061Member" xlink:href="lly-20260805.xsd#lly_A1375NotesDue2061Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A1375NotesDue2061Member" xlink:to="lab_lly_A1375NotesDue2061Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_019f8a77-cc87-74cf-aa44-5aea901c8f90_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_019f8a77-cc87-7229-8fa8-f581bf1e4fd4_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_019f8a77-cc87-70aa-9cf0-2be5fbcdef36_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_019f8a77-cc87-7b9d-a53b-d1a270d705fe_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A6.77NotesDueJanuary12036Member_019f8a77-cc87-764b-8e7d-2a8f51b716a1_terseLabel_en-US" xlink:label="lab_lly_A6.77NotesDueJanuary12036Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">6.77% Notes due 2036</link:label>
    <link:label id="lab_lly_A6.77NotesDueJanuary12036Member_label_en-US" xlink:label="lab_lly_A6.77NotesDueJanuary12036Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">6.77%&#160;Notes Due January&#160;1, 2036 [Member]</link:label>
    <link:label id="lab_lly_A6.77NotesDueJanuary12036Member_documentation_en-US" xlink:label="lab_lly_A6.77NotesDueJanuary12036Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">6.77%&#160;Notes Due January&#160;1, 2036 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A6.77NotesDueJanuary12036Member" xlink:href="lly-20260805.xsd#lly_A6.77NotesDueJanuary12036Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A6.77NotesDueJanuary12036Member" xlink:to="lab_lly_A6.77NotesDueJanuary12036Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_019f8a77-cc87-7441-b5e0-812e445e48a4_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_019f8a77-cc87-7a9a-9eea-8650ec608f80_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A2.125NotesDueJune32030Member_019f8a77-cc87-78fa-801c-01b1599e4934_terseLabel_en-US" xlink:label="lab_lly_A2.125NotesDueJune32030Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2.125% Notes due 2030</link:label>
    <link:label id="lab_lly_A2.125NotesDueJune32030Member_label_en-US" xlink:label="lab_lly_A2.125NotesDueJune32030Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2.125% Notes Due June 3, 2030 [Member]</link:label>
    <link:label id="lab_lly_A2.125NotesDueJune32030Member_documentation_en-US" xlink:label="lab_lly_A2.125NotesDueJune32030Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2.125% Notes Due June 3, 2030 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A2.125NotesDueJune32030Member" xlink:href="lly-20260805.xsd#lly_A2.125NotesDueJune32030Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A2.125NotesDueJune32030Member" xlink:to="lab_lly_A2.125NotesDueJune32030Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_019f8a77-cc87-7501-b8d6-800adfa2fd43_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A500NotesDue2033Member_019f8a77-cc87-72b3-83f6-69621aa97601_terseLabel_en-US" xlink:label="lab_lly_A500NotesDue2033Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">0.500% Notes due 2033</link:label>
    <link:label id="lab_lly_A500NotesDue2033Member_label_en-US" xlink:label="lab_lly_A500NotesDue2033Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">.500% Notes due 2033 [Member]</link:label>
    <link:label id="lab_lly_A500NotesDue2033Member_documentation_en-US" xlink:label="lab_lly_A500NotesDue2033Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">0.500% Notes due 2033</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A500NotesDue2033Member" xlink:href="lly-20260805.xsd#lly_A500NotesDue2033Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A500NotesDue2033Member" xlink:to="lab_lly_A500NotesDue2033Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentInformationTable_019f8a77-cc87-760c-8bca-913d213a9f3f_terseLabel_en-US" xlink:label="lab_dei_DocumentInformationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Information [Table]</link:label>
    <link:label id="lab_dei_DocumentInformationTable_label_en-US" xlink:label="lab_dei_DocumentInformationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentInformationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationTable" xlink:to="lab_dei_DocumentInformationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonClassAMember_019f8a77-cc87-759a-b03e-888cda5c76a7_terseLabel_en-US" xlink:label="lab_us-gaap_CommonClassAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock (no par value)</link:label>
    <link:label id="lab_us-gaap_CommonClassAMember_label_en-US" xlink:label="lab_us-gaap_CommonClassAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Class A [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonClassAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonClassAMember" xlink:to="lab_us-gaap_CommonClassAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_019f8a77-cc87-72e6-90b2-06c49aef464c_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_019f8a77-cc87-7734-ac2a-f80829c3254c_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_019f8a77-cc87-775e-a339-e737dc8e6bd0_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_019f8a77-cc87-7213-bffb-fd095cc11c42_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_019f8a77-cc87-7940-b935-cc975b5726da_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A625Notesdue2031Member_019f8a77-cc87-720e-977d-b6ae79898bea_terseLabel_en-US" xlink:label="lab_lly_A625Notesdue2031Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">0.625% Notes due 2031</link:label>
    <link:label id="lab_lly_A625Notesdue2031Member_label_en-US" xlink:label="lab_lly_A625Notesdue2031Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">.625% Notes due 2031 [Member]</link:label>
    <link:label id="lab_lly_A625Notesdue2031Member_documentation_en-US" xlink:label="lab_lly_A625Notesdue2031Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">.625% Notes due 2031 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A625Notesdue2031Member" xlink:href="lly-20260805.xsd#lly_A625Notesdue2031Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A625Notesdue2031Member" xlink:to="lab_lly_A625Notesdue2031Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentInformationLineItems_019f8a77-cc87-71a3-a312-a2b1f8cee82b_terseLabel_en-US" xlink:label="lab_dei_DocumentInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:label id="lab_dei_DocumentInformationLineItems_label_en-US" xlink:label="lab_dei_DocumentInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationLineItems" xlink:to="lab_dei_DocumentInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_019f8a77-cc87-782e-a125-12e4f78a38cf_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_019f8a77-cc87-7493-a23b-fd404875aed2_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_019f8a77-cc87-77b8-a170-137ac9925be7_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_019f8a77-cc87-7393-b5e0-8b66866b54ba_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_019f8a77-cc87-7a95-b365-0b0ef54e6456_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>lly-20260805_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:019f8a77-cc87-70d8-bcd7-b8b7964653b4,g:c8da2307-0382-494c-ac1c-f110104979d9-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.lilly.com/role/CoverPage" xlink:type="simple" xlink:href="lly-20260805.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_019f8a77-cc87-7c26-a73e-b7b4dd28862c" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable_019f8a77-cc87-7983-9105-d26e767514ae" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentInformationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019f8a77-cc87-7c26-a73e-b7b4dd28862c" xlink:to="loc_dei_DocumentInformationTable_019f8a77-cc87-7983-9105-d26e767514ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_019f8a77-cc87-7555-9c16-3748ceb8b93a" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_019f8a77-cc87-7983-9105-d26e767514ae" xlink:to="loc_us-gaap_StatementClassOfStockAxis_019f8a77-cc87-7555-9c16-3748ceb8b93a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_019f8a77-cc87-7da8-80fb-c5f57f0653ba" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_019f8a77-cc87-7555-9c16-3748ceb8b93a" xlink:to="loc_us-gaap_ClassOfStockDomain_019f8a77-cc87-7da8-80fb-c5f57f0653ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_019f8a77-cc87-7a06-bd2d-5ad0091e1632" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_019f8a77-cc87-7da8-80fb-c5f57f0653ba" xlink:to="loc_us-gaap_CommonClassAMember_019f8a77-cc87-7a06-bd2d-5ad0091e1632" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A2.125NotesDueJune32030Member_019f8a77-cc87-7f4a-bf35-4ef66bf9d2ca" xlink:href="lly-20260805.xsd#lly_A2.125NotesDueJune32030Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_019f8a77-cc87-7da8-80fb-c5f57f0653ba" xlink:to="loc_lly_A2.125NotesDueJune32030Member_019f8a77-cc87-7f4a-bf35-4ef66bf9d2ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A625Notesdue2031Member_019f8a77-cc87-794f-9a4f-11e51952a398" xlink:href="lly-20260805.xsd#lly_A625Notesdue2031Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_019f8a77-cc87-7da8-80fb-c5f57f0653ba" xlink:to="loc_lly_A625Notesdue2031Member_019f8a77-cc87-794f-9a4f-11e51952a398" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A6.77NotesDueJanuary12036Member_019f8a77-cc87-749f-8a65-96a3a388c7bf" xlink:href="lly-20260805.xsd#lly_A6.77NotesDueJanuary12036Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_019f8a77-cc87-7da8-80fb-c5f57f0653ba" xlink:to="loc_lly_A6.77NotesDueJanuary12036Member_019f8a77-cc87-749f-8a65-96a3a388c7bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1.700Notesdue2049Member_019f8a77-cc87-7397-8424-333c9e6acc59" xlink:href="lly-20260805.xsd#lly_A1.700Notesdue2049Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_019f8a77-cc87-7da8-80fb-c5f57f0653ba" xlink:to="loc_lly_A1.700Notesdue2049Member_019f8a77-cc87-7397-8424-333c9e6acc59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A500NotesDue2033Member_019f8a77-cc87-7bbd-878f-d31e693825e8" xlink:href="lly-20260805.xsd#lly_A500NotesDue2033Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_019f8a77-cc87-7da8-80fb-c5f57f0653ba" xlink:to="loc_lly_A500NotesDue2033Member_019f8a77-cc87-7bbd-878f-d31e693825e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1625NotesDue2043Member_019f8a77-cc87-7bff-8b0c-cf802b927ce1" xlink:href="lly-20260805.xsd#lly_A1625NotesDue2043Member"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_019f8a77-cc87-7da8-80fb-c5f57f0653ba" xlink:to="loc_lly_A1625NotesDue2043Member_019f8a77-cc87-7bff-8b0c-cf802b927ce1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1125NotesDue2051Member_019f8a77-cc87-7128-baa1-dff99fa1ca14" xlink:href="lly-20260805.xsd#lly_A1125NotesDue2051Member"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_019f8a77-cc87-7da8-80fb-c5f57f0653ba" xlink:to="loc_lly_A1125NotesDue2051Member_019f8a77-cc87-7128-baa1-dff99fa1ca14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1375NotesDue2061Member_019f8a77-cc87-7f74-87da-2885adb880dc" xlink:href="lly-20260805.xsd#lly_A1375NotesDue2061Member"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_019f8a77-cc87-7da8-80fb-c5f57f0653ba" xlink:to="loc_lly_A1375NotesDue2061Member_019f8a77-cc87-7f74-87da-2885adb880dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems_019f8a77-cc87-7617-9ba8-94b1e0cd9892" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentInformationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_019f8a77-cc87-7983-9105-d26e767514ae" xlink:to="loc_dei_DocumentInformationLineItems_019f8a77-cc87-7617-9ba8-94b1e0cd9892" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_019f8a77-cc87-7d4b-9634-75d0791110bf" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_019f8a77-cc87-7617-9ba8-94b1e0cd9892" xlink:to="loc_dei_DocumentType_019f8a77-cc87-7d4b-9634-75d0791110bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_019f8a77-cc87-72a6-83f9-f79c0a7d3582" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_019f8a77-cc87-7617-9ba8-94b1e0cd9892" xlink:to="loc_dei_DocumentPeriodEndDate_019f8a77-cc87-72a6-83f9-f79c0a7d3582" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_019f8a77-cc87-7acd-8611-dbdb1aa389ba" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_019f8a77-cc87-7617-9ba8-94b1e0cd9892" xlink:to="loc_dei_EntityIncorporationStateCountryCode_019f8a77-cc87-7acd-8611-dbdb1aa389ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_019f8a77-cc87-7406-b7c4-dfd32bc57576" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_019f8a77-cc87-7617-9ba8-94b1e0cd9892" xlink:to="loc_dei_EntityFileNumber_019f8a77-cc87-7406-b7c4-dfd32bc57576" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_019f8a77-cc87-7b07-9baf-0d58f56f474f" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_019f8a77-cc87-7617-9ba8-94b1e0cd9892" xlink:to="loc_dei_EntityTaxIdentificationNumber_019f8a77-cc87-7b07-9baf-0d58f56f474f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_019f8a77-cc87-7f12-bf25-04f227eaea73" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_019f8a77-cc87-7617-9ba8-94b1e0cd9892" xlink:to="loc_dei_EntityAddressAddressLine1_019f8a77-cc87-7f12-bf25-04f227eaea73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_019f8a77-cc87-7e1e-917f-25e5f3293ba2" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_019f8a77-cc87-7617-9ba8-94b1e0cd9892" xlink:to="loc_dei_EntityAddressCityOrTown_019f8a77-cc87-7e1e-917f-25e5f3293ba2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_019f8a77-cc87-7f9a-bcdd-3779e7d81594" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_019f8a77-cc87-7617-9ba8-94b1e0cd9892" xlink:to="loc_dei_EntityAddressStateOrProvince_019f8a77-cc87-7f9a-bcdd-3779e7d81594" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_019f8a77-cc87-7418-b018-4d5289019617" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_019f8a77-cc87-7617-9ba8-94b1e0cd9892" xlink:to="loc_dei_EntityAddressPostalZipCode_019f8a77-cc87-7418-b018-4d5289019617" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_019f8a77-cc87-7fa6-9083-57634c136bab" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_019f8a77-cc87-7617-9ba8-94b1e0cd9892" xlink:to="loc_dei_CityAreaCode_019f8a77-cc87-7fa6-9083-57634c136bab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_019f8a77-cc87-7077-a851-23eca7e4196f" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_019f8a77-cc87-7617-9ba8-94b1e0cd9892" xlink:to="loc_dei_LocalPhoneNumber_019f8a77-cc87-7077-a851-23eca7e4196f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_019f8a77-cc87-7657-a4de-d820e26d5b67" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_019f8a77-cc87-7617-9ba8-94b1e0cd9892" xlink:to="loc_dei_WrittenCommunications_019f8a77-cc87-7657-a4de-d820e26d5b67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_019f8a77-cc87-74da-9c0a-e0fe341d0387" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_019f8a77-cc87-7617-9ba8-94b1e0cd9892" xlink:to="loc_dei_SolicitingMaterial_019f8a77-cc87-74da-9c0a-e0fe341d0387" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_019f8a77-cc87-727a-bc2e-fd9a59cfbdcd" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_019f8a77-cc87-7617-9ba8-94b1e0cd9892" xlink:to="loc_dei_PreCommencementTenderOffer_019f8a77-cc87-727a-bc2e-fd9a59cfbdcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_019f8a77-cc87-7463-8136-8c2a7bdb08be" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_019f8a77-cc87-7617-9ba8-94b1e0cd9892" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_019f8a77-cc87-7463-8136-8c2a7bdb08be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_019f8a77-cc87-7bdb-9d34-cf1ea95f5f4a" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_019f8a77-cc87-7617-9ba8-94b1e0cd9892" xlink:to="loc_dei_EntityEmergingGrowthCompany_019f8a77-cc87-7bdb-9d34-cf1ea95f5f4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_019f8a77-cc87-7a43-b726-ad4d57c800d0" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_019f8a77-cc87-7617-9ba8-94b1e0cd9892" xlink:to="loc_dei_Security12bTitle_019f8a77-cc87-7a43-b726-ad4d57c800d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_019f8a77-cc87-7ec9-9563-659968761435" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_019f8a77-cc87-7617-9ba8-94b1e0cd9892" xlink:to="loc_dei_TradingSymbol_019f8a77-cc87-7ec9-9563-659968761435" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_019f8a77-cc87-770f-a007-5a0c16c424f5" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_019f8a77-cc87-7617-9ba8-94b1e0cd9892" xlink:to="loc_dei_SecurityExchangeName_019f8a77-cc87-770f-a007-5a0c16c424f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_019f8a77-cc87-7f39-a98e-ec0a2b89949a" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_019f8a77-cc87-7617-9ba8-94b1e0cd9892" xlink:to="loc_dei_EntityRegistrantName_019f8a77-cc87-7f39-a98e-ec0a2b89949a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_019f8a77-cc87-750b-b460-914ba7fc0a11" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_019f8a77-cc87-7617-9ba8-94b1e0cd9892" xlink:to="loc_dei_EntityCentralIndexKey_019f8a77-cc87-750b-b460-914ba7fc0a11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_019f8a77-cc87-7cca-a6ae-0fb9c46dea56" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_019f8a77-cc87-7617-9ba8-94b1e0cd9892" xlink:to="loc_dei_AmendmentFlag_019f8a77-cc87-7cca-a6ae-0fb9c46dea56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>logoa31a.jpg
<TEXT>
begin 644 logoa31a.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0!:17AI9@  34T *@    @ !0,!  4
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M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
M 0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9
M&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"
M@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2
MT]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /W\HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_P *N\.7.;BYMSQXINDX\WC_ )=XS_JTZ.?GY_=^7]'?\' /_!4K_A#;&\^
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MQCJQ3BFI*.JGHI1<79Z]-;K6ZMK^EU%%%?8G\VA1110 4444 %%%% !1110
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M[XA_MM+<>'/#ZMX#^&]T?(N=+MIQ]NUB+'6ZG_N?],8\1_.0_F8!KR?]A/\
MX)O_ !%_;\\<K;>%-+:S\.VMR(=6\2WH"Z?I_0G'_/:7 SY4?/SIGRX_WE?H
M=^P]_P &V6D^&'L]:^.6N_V]= B8>&M'N)(;,=<_:;CAY.WR1[,%!^\<9%?I
MM&G@W]G7X;6]NO\ PCO@GPEH-OY40_<Z9INGQCL/NQQK]*^GPO#6+QU3ZUFT
MVEVZV_**/P?/_&OA[AC!?V#X?8=3EMSJ+Y%+175_>JROU;M>VLH^Z>4_L+_\
M$]/ /_!/SX9-HOA>U^U:OJ0#:SKUV,WNKS#GG&?+B'\$*<#J<N7D?Z.KF?!/
MQ!T7XD>%K?5O#NN:9X@TNZ'[B^L+B.ZAF'M)&2OY5TU?H%"C2I4U"BDHK:VQ
M_)&;9ECL?C*F+S*<IUI.\G*][^=]5;HMDK)605^:?_!9?_@LLO[*VF77PX^&
M=U;77Q&NX#_:&H ^;#X9B?CMP]T>PZ1CDY/%>E?\%D?^"F-I^P9\%6TK0;JW
M?XH>,898-'C9!,-(A^Z]^Z$8^3CRU;AY,\.D<@'X/_!3X->,_P!L;X]:;X9\
M.VMYKOBKQ5J.6FN)GER7.^>>67G]V,O)(Y]Z^0XES^5&2P.#UJ2W:W5^B\W^
M'S/Z)\#_  DPV8TGQ3Q(E'!T[N,9:*?+?FG+I[.-NOQ/R7O7/@5\!O'7[9_Q
MOM?#'A:SN_$7BW7)YKVZN9II#@>9F>[N)VR53+_.[\DOCEWY_<3]E;_@G]\'
M_P#@CM\ =4^(WBR\L]4\3:+8?:-7\37$(\R#.$^S649/R!W<(H_UDCR =-D:
M>G_L)_L(> O^"9O[/]Q;6MQ;2:E) M]XI\3WRK UR8TWO([O_JK>/YMB9P@R
M3\Y=S^0?_!9;_@JK<?MU?$=O"?A.YNK/X7^&;H_8 V8F\0W8RGVR1/X(N3Y<
M9Z(=[X=_+C\RG@Z&28?ZUB;3KR^%/6S_ ,EU9]IC.)<U\4L[>0Y&Y4,JI6]K
M->ZYQ6EG:UN9*T(?]O26EE\P?M1?'[6_VN?VA_$WC[6+?_B8>+]2^T"V@'F_
M9XN(X+=/[^R-(T_X!7]#7_!)G]DF7]C7]B'PGX9U*U6U\3:CG6M>7'S"\N0G
M[MQ_?AB2& _]<>*_-?\ X-__ /@FA)\9_B+:_&SQIII_X1'P?<Y\.VUQ#\NK
MZC'C_20?XHX&'4?\MQU_=O'7Z#?\%6_^"G>A_P#!/7X1,ME]GU3XC>)('30-
M)9CY<'4&]N>X@C/1!S(_R @>9)'MPSAXX:E4S?&NW-?5]F[M^KZ(\_QMSR>=
MX_">'/"]/F5)QYE';FC'EC"^RC3BVY-NR;ULXNW6?MX?\%*_AU_P3[\%K=^*
MKIM5\1:E ?[(\/V#)]MU C(+GM#"".9'.#@A!(_R5^*G[7'_  6N^/'[5FH7
M5O#XFO/ 7ALMNM]*\,W#V96+G_73_P"OFX^^/,$9Q]Q.:\(DE^(W[<G[1/S?
MVMX^^(GC?4>/^6UQ=S_I''%'&/\ 82-$_@C3C]EOV1_^"3'PA_X)G_!:]^*?
MQ@72_%?C#0;!M1U#4+J(3Z=H>P[Q':02#$DF_8B2.#(\@7RPA?:>>6/S#.:C
MCAW[.C'=[67F^NG1/2^I[6'X5X.\,,'2J9O36.S*K;D@DI-R;2M"$KJ*YG93
MDG.3^'>Q^&=EXIU*V\3#68-2O+?4A<^>-0%P_P!H\W_GIYGWZ_H3_P""&7[5
M'BS]J+]AJSU3QI>7FJ:UX8UFX\.MJ%RWFSW\*1P3Q/*Y^^X2=8]_5RGS_/FO
MP5_:4^--Q^T1\?/&7CBYMC:GQ1JUQJ9M_P#GWBDD/EQ_]LTPE?T5?\$H/V7;
MC]D#]A;P/X3U2U6R\130-JFLPLHW0W5TV\QO_MQIY<)_ZY5CP73FL?4<&W!)
MW??6R^_<]+Z36(PG^JV$6+I1CBISBXK1N"4;U$I63Y5=1>R;:=M%;Z?HHHK]
M./X5"BBB@ HHHH **** "BBB@ HHHH **P?&/C31_!6D_:]:U+3M)M>\UY<I
M#&#]6XKC]'_:W^%?B'4OLMC\3_A_>72C_4V_B"SED_(.36<JL(Z2:7S.JC@<
M36BYT:<I);M1;7WI6/3J^)?VKO\ @A5\!?VHM1FU.'0[KP#X@NL2W&H>&C':
MQW/!'[RW='@]\HB2?[=?:-E<PWL(GA93&1UJS6>*P=#$1Y*\5)>?]7._).(L
MTR:O]9RK$3HS[Q;5_)K:2\FFC\3?BI_P:T^-=+"_\(7\4/"NL=]NL:=<::1_
MP*'SZ\WU'_@VK_:"TU_WFK?#(PVXSYW]KS^5C_@=K7[]5^-O_!>/_@K>FLC4
M_@1\,]2WV^3;>+M6MIL>?V?3HW_N <3G_MGT\P'X[.,BRC!T'7J1:[)/=]E>
M_P _(_I/PX\6/$;B7,X95A*D)]9U)4U[D+ZRER\J\DDDV[+K=?E/XP\+_P#"
M(>,=1TR/4M)U3^S[F6#^T+!GFL[C8_\ K(7=$WQ^AKZ8_P""4_\ P3%U/_@H
MK\5+JWO;B^T+X?\ AN -J^K0*AE\Y_\ 5V\)?CS9.7/!$<:<_?3?X_\ LD?L
ML^*/VS/CKH/@'PE:;]4U-_\ 2+GEH=/M4_UEQ/C[L<?\]B#YW3/]*'[(_P"R
MOX6_8U^!>A^ O"5ILTW3!NN+@E?.U&Y?!DN9SW=SZ=!L081!7SG#.0_7:SK5
M5^ZB_O?;T[G[%XX>*[X6RV.68"HGCJJ5G9?NX]9M;<S::BFK7O+515_!?@/_
M ,$%_P!G+X$F"XG\+7?C;4K/E;GQ-?&\'XP((X'_ .!QFOKSPEX4TOP-H%OI
M6CZ;9Z3IMHOE06UE D,, _V$3A17045^I8? X?#JU""CZ*WX[_>?P;GG$V;9
MS5]KFN)G6?3GDY6]$W9>22T"OP>_X.6?B=XLU;]LS0?">H3W,?A/3_#T%[I=
MBK?N+F6:2<27'^_^[V?]LJ_07XK?\%O?@S\&_P!KVW^%NIZI=/;VH:VU?Q+#
MB73-(U#^&VE.,D<.)'3_ %<A1#D^9Y?L7[3W[&?PG_;R\&:.GCC0;/Q59VP^
MUZ3J%M<O%-#YBCF*>%P?+<!25SY;X4X->/G%&&:86>&PE1.46KZ]NC/T?P\Q
M]?@7/<+G?$&"G[&K"7(^76TEI."=DVENFT^65]FK_D'_ ,&W/Q$\3:7^W)<^
M&M-N+J3PWKV@74^L6N?W*B#RS#<[/[X=T3=Z3FOVY^.'Q@T']GWX5Z]XU\1W
M!M=#\,V,M_=3J 3L3G8@_B=SA47N2.]<1^R'^P3\+OV)=!OK7X>^&_[+FU3
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M5M7:2=^H_P""Q?\ P67O?VN]5O/AS\/+V[T_X8V5SMN[U6,,_BB6-NI_N6W
M*)_']]_[B>8?\$GO^"8&N?\ !0CXK"\U);K2/A?X:N -9U11M-W+_K!90_\
M3608,AZ)&^2?WB));_X)9_\ !(?Q=^WYXCM]<U877AWX8:9<;+_5BO[[4"GW
M[:S#??D]7_U<?/WS^[K]_/@O\&O#O[/WPXTGPCX3T>TT/PYH4/DVEC ORP<Y
M)SU=G<EV=\N[N7))S7?E.4XC-L1_:&/^#HMKKHDND?S/EN/O$+)_#_*/]4>#
M[?6$K3FK/D;6LI/[55[)?8LN9:*)S?QD^)_@W]A/]EK5/$-Q96VD^$? >E8M
M;"W(B#!!Y<%K#G^*20QQI[N*_FI_:)^/7C']M7]HC5O%FO/=ZIXF\4:@(;;3
M[??-]FW2;(K2&/KL3*(@'7.?]8_/Z'_\',?[7Q\0_$+PS\%-(NU6TT&W&MZ^
M!T-U(,6L3GUC@,DG_;=*PO\ @WW_ &,=%_M'7/VBOB$MII?AGP(TL.CSWY\F
MS^U(G^D7KE_DV01OLC?IYCR'AX:6>5IYEF$<LH:0COVTW?HELO7N8^%67X7@
MK@^MQQFD7/$XCX$_B:;M"*>KO5E[[>ONVE;W=?MS_@D5_P $QM#_ .">WP8/
MB;Q4+3_A8^N6(EUK49F3RM%M<"3[%&X^1$3@R/\ QNG]R-,?G+_P6O\ ^"LC
M?MC>-6^'W@*Z;_A5_ANYS/<+T\1W2$C[1_UPCSB-.Y^<\^7Y>E_P5Q_X+67W
M[6JW/P]^%]U>:3\-1^XU'4/G@O/$_P!4^_'!U_=\._\ &!_JZX/_ (),_P#!
M(WQ#^WIXTM?$WB);S0_A;I=Q_I6H+^ZN-9E3_EWM?R(D?_EGSUDZ9X[&?6.7
M)LH7N=6NO>[[=WU/4X1X7EE$JOB3XBU+5W[T(/7V=_A2CK[]O=A!? KN3YKN
M/IG_  02_P""9<W[0GQ.M/B]XRTN0>!?!UUYND6UP,CQ!J"?Q?[4$$@#D]'?
M8F9!'(!^\%<SX!\!Z'\,/!6G^'?#NGVND:+HMNMG8V-NOEQ6T2# C0>@%5=9
M^)/ASP]XLTG0]2U[1[/7O$ F_LJQFNHX[K4?) >7R8\[Y-@QNV9P.M?;9/E5
M++\.J,7J]WW?^1_+GB+QYCN,<YGF%6+4(IJG!:\D%=ZVNKOXIO\ **5NPHHH
MKUC\^"BBO"_@+^W9\*?VF_B'XD\*>"_&^DZ[K7AF9H;FW@8[IU39NFA)_P!=
M"&;89(_DSWPZ$YRK0C)1DTF]O/T.O#Y?BJ]*I7HTY2A32<VDVHINR<FE9)O:
M]K]#W2BBBM#D"BBB@ HHHH *_*?_ (+._P#!:76?V>?&EY\*/A+=PV7B>Q$7
M_"0:\]OYO]G%UW_9;8/^[,I1H]\G(CW;!\^3'^K%?RO_ /!0C2M0T?\ ;U^,
MUOJ@N/[0/C#6)LRGM)>2/&_^X8W0C\*^3XNS&MA<+&-!\KD[7[)+]3^@OHZ\
M%Y9GV?U*F:152-""DH/52DVDFUU4=[;-VOIH^;BTSXG_ +7OQ$N[B&U\=?$S
MQ,1F<B&ZUB[,?O\ ZR3%=%XH_P""?7QR\(Z;]IU3X._$RSM<>;YY\+W?E#_?
M/E_)7Z[_ /!#3]L'X$^&OV/_  SX(T[7/"W@SQQ;M,VNZ=?W45G=ZM=;WS<(
M\F/M.8PF-I/EHH3I'Q]V^)/VBO /@S2/M>L^.O!VCVH_Y;7NL6\,?_?;OBO!
MP/"N'Q.'6(J5]9*[>FE^COK<_6N*?I 9UDN<5,HPF4VITY.,5+F3DD[)Q44D
MHNUU9/3J?R^_!?\ :<^)'[,7B'[5X%\8^*/"=T+C,]MI^H20PW$O_3:#_5R?
M]M$-?H_^Q+_P<J:SI&HV^B_'315U*Q_U)\3:3;^1>1'IOGM1^[?W,'EX XC<
MUZW_ ,%.OVU?V'_BEH=Y;^+K>Q^)?BKR0+;4/"-N/[1MNOEXU+Y(?+&.4\R3
MK_JWZ5^)>L26LNH7(L[>[M=/\[]S#/-YT@C_ (-SA$WM_P  2O)K5L1D]91P
MN(4UV3NOFM5]S9]]E>5Y1XCY;*OG^33PM33WY149.Z^*%1*,VEUYHJ+TT?3]
M<O\ @K9_P7GL-5\,W7P^^ VJ-<G4;?&L^+[??%]GC=/^/>R/#^9C[\P \OHG
M[SYX_P L_@A\#_%7[2/Q4TOP7X/TVZU3Q%K$_DP01=%'\<LAQ\D:<EW/85Q=
M?KC_ ,$3OVZ?V6_V:OAZNB:NU[X*^)&I8_M;7=<A\ZWU%O\ GG!<1I^Y@'79
M(B<]7D(S4T\1+.,<OKM10CTZ)+LNEWYL[,9E%+PVX6G#A?!3Q%5[M+FE*5G[
M]3EM)QBME%65K>ZFY+[O_P""9W_!.?PW_P $]?@FNFV;6^J^+M<$<WB'5_+Y
MNI@,B*/H5@CZ(/<OU<X^J*\NT3]L+X3^*='_ +2TWXF_#^\L"/\ CX@\16LD
M/XL'KP[]HC_@MM^SO^SWIS?\5[8^-=29,V]AX7/]K-.?^NZ'R%_X'(*_4X5L
M%A*,8J<8P6VJ/X+Q&5\3\19I4KU,/5KXBI*\O<DW?ST2C%;):)+8^OI9Q /G
MK\>_^"N__!>*"[T_4?AM\"M;4_:#]FU;QAI\W;^.+3Y!WZ?Z2/\ MGVD'RS_
M ,%"?^"UWQ._;B-YX:TUE\"?#VZ)7^R=/N2;C4(NQNI^#)G'W$V1\_Q\/7QG
M>Z/<Z9':M-:W-K]JMQ/;^>,>?$?XTKX//N+G53H8&Z766S?IU2\^I_5GA/\
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M;5ET'X:^#=.@M[;0M.8B#4;L?O)[VXDX\Z629Y).?W<?1.=[OX?7ZW?\$'_
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MQ1VNP_N4C_@V=_GSOYK@=2FN-1>XU"\:ZNKB\N9?.N9_W@GE^^_[S^*3Y_\
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MIO\ PK6^NO"O_"-W$6HWWBZ%G6#0$!P?NX\R=_GV0_\ +3G.Q-\@B_X)Q?\
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M\[(ER,EXB4^Z2A)?97YMZ]^P!\<_"^I?V?>_!OXEI= ]!X8O)@?^N;I'L?\
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MX"?#KX?^*OVC_BMIOAO0[.\U[Q1XNU 06ZD^=-<SR.=\LC_F[N_^VY]:[/\
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MHHHK8\\**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
6444 %%%% !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover Page<br></strong></div></th>
<th class="th"><div>Aug. 05, 2026</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Aug.  05,  2026<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">IN<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-06351<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">35-0470950<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">Lilly Corporate Center<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Indianapolis,<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">IN<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">46285<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">317<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">276-2000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ELI LILLY AND COMPANY<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000059478<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Stock (no par value)</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock (no par value)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LLY<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lly_A2.125NotesDueJune32030Member', window );">2.125% Notes due 2030</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">2.125% Notes due 2030<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LLY30<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lly_A625Notesdue2031Member', window );">0.625% Notes due 2031</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">0.625% Notes due 2031<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LLY31<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lly_A6.77NotesDueJanuary12036Member', window );">6.77% Notes due 2036</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">6.77% Notes due 2036<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LLY36<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lly_A1.700Notesdue2049Member', window );">1.700% Notes due 2049</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">1.700% Notes due 2049<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LLY49A<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lly_A500NotesDue2033Member', window );">0.500% Notes due 2033</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">0.500% Notes due 2033<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LLY33<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lly_A1625NotesDue2043Member', window );">1.625%&#160;Notes due 2043</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">1.625% Notes due 2043<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LLY43<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lly_A1125NotesDue2051Member', window );">1.125% Notes due 2051</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">1.125% Notes due 2051<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LLY51<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lly_A1375NotesDue2061Member', window );">1.375% Notes due 2061</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">1.375% Notes due 2061<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LLY61<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lly_A2.125NotesDueJune32030Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lly_A2.125NotesDueJune32030Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lly_A625Notesdue2031Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lly_A625Notesdue2031Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lly_A6.77NotesDueJanuary12036Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lly_A6.77NotesDueJanuary12036Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lly_A1.700Notesdue2049Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lly_A1.700Notesdue2049Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lly_A500NotesDue2033Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lly_A500NotesDue2033Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lly_A1625NotesDue2043Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lly_A1625NotesDue2043Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lly_A1125NotesDue2051Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lly_A1125NotesDue2051Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lly_A1375NotesDue2061Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lly_A1375NotesDue2061Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.26.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>10</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>9</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="lly-20260805.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="lly-20260805.htm">lly-20260805.htm</File>
    <File>lly-20260805.xsd</File>
    <File>lly-20260805_def.xml</File>
    <File>lly-20260805_lab.xml</File>
    <File>lly-20260805_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="46">http://xbrl.sec.gov/dei/2026</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "lly-20260805.htm": {
   "nsprefix": "lly",
   "nsuri": "http://www.lilly.com/20260805",
   "dts": {
    "inline": {
     "local": [
      "lly-20260805.htm"
     ]
    },
    "schema": {
     "local": [
      "lly-20260805.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd",
      "https://xbrl.fasb.org/srt/2026/elts/srt-roles-2026.xsd",
      "https://xbrl.fasb.org/srt/2026/elts/srt-types-2026.xsd",
      "https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd",
      "https://xbrl.fasb.org/us-gaap/2026/elts/us-roles-2026.xsd",
      "https://xbrl.fasb.org/us-gaap/2026/elts/us-types-2026.xsd",
      "https://xbrl.sec.gov/country/2026/country-2026.xsd",
      "https://xbrl.sec.gov/dei/2026/dei-2026.xsd",
      "https://xbrl.sec.gov/stpr/2026/stpr-2026.xsd"
     ]
    },
    "definitionLink": {
     "local": [
      "lly-20260805_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "lly-20260805_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "lly-20260805_pre.xml"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 1,
   "axisCustom": 0,
   "memberStandard": 1,
   "memberCustom": 8,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2026": 2
   },
   "contextCount": 10,
   "entityCount": 1,
   "segmentCount": 9,
   "elementCount": 36,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2026": 46
   },
   "report": {
    "R1": {
     "role": "http://www.lilly.com/role/CoverPage",
     "longName": "0000001 - Document - Cover Page",
     "shortName": "Cover Page",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lly-20260805.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lly-20260805.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "lly_A1.700Notesdue2049Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.lilly.com/20260805",
     "localname": "A1.700Notesdue2049Member",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "1.700% Notes due 2049",
        "label": "1.700% Notes due 2049 [Member]",
        "documentation": "1.700% Notes due 2049 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "lly_A1125NotesDue2051Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.lilly.com/20260805",
     "localname": "A1125NotesDue2051Member",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "1.125% Notes due 2051",
        "label": "1.125% Notes due 2051 [Member]",
        "documentation": "1.125% Notes due 2051"
       }
      }
     },
     "auth_ref": []
    },
    "lly_A1375NotesDue2061Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.lilly.com/20260805",
     "localname": "A1375NotesDue2061Member",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "1.375% Notes due 2061",
        "label": "1.375% Notes due 2061 [Member]",
        "documentation": "1.375% Notes due 2061"
       }
      }
     },
     "auth_ref": []
    },
    "lly_A1625NotesDue2043Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.lilly.com/20260805",
     "localname": "A1625NotesDue2043Member",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "1.625%\u00a0Notes due 2043",
        "label": "1.625%\u00a0Notes due 2043 [Member]",
        "documentation": "1.625%\u00a0Notes due 2043"
       }
      }
     },
     "auth_ref": []
    },
    "lly_A2.125NotesDueJune32030Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.lilly.com/20260805",
     "localname": "A2.125NotesDueJune32030Member",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2.125% Notes due 2030",
        "label": "2.125% Notes Due June 3, 2030 [Member]",
        "documentation": "2.125% Notes Due June 3, 2030 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "lly_A500NotesDue2033Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.lilly.com/20260805",
     "localname": "A500NotesDue2033Member",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "0.500% Notes due 2033",
        "label": ".500% Notes due 2033 [Member]",
        "documentation": "0.500% Notes due 2033"
       }
      }
     },
     "auth_ref": []
    },
    "lly_A6.77NotesDueJanuary12036Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.lilly.com/20260805",
     "localname": "A6.77NotesDueJanuary12036Member",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "6.77% Notes due 2036",
        "label": "6.77%\u00a0Notes Due January\u00a01, 2036 [Member]",
        "documentation": "6.77%\u00a0Notes Due January\u00a01, 2036 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "lly_A625Notesdue2031Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.lilly.com/20260805",
     "localname": "A625Notesdue2031Member",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "0.625% Notes due 2031",
        "label": ".625% Notes due 2031 [Member]",
        "documentation": ".625% Notes due 2031 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Domain]",
        "label": "Class of Stock [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonClassAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "CommonClassAMember",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock (no par value)",
        "label": "Common Class A [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cover [Abstract]",
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "DocumentInformationLineItems",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Information [Line Items]",
        "label": "Document Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "DocumentInformationTable",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Information [Table]",
        "label": "Document Information [Table]",
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "DocumentType",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Issuer Tender Offer",
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Tender Offer",
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Soliciting Material",
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Axis]",
        "label": "Class of Stock [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Written Communications",
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0000059478-26-000077-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000059478-26-000077-xbrl.zip
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M#F'A$N*(AOT)+YD6\'N@/8F+)3U1%#QO7\= )T#8FV1I?5CV^T^L'#/X*/.
MA0!6;S'NDQG7(7;JR:SSQK)<E49(R%MAT:_$(P%8&!T/>!ASQRMJBHIX6L^C
M;?J:PQU'L8>JB%9M/WN,^Z-D2:*I&(?8K=S'4J\)H]Q%WSQJPV2.OG9!#;$7
M"L5UL>!ZY(^ 1@ :S*T=>ZG'-5Q>Z?5\W^UA0( (<&AJ$*@,3BU3T\Y??ZWR
M/M?;J]F?,A6Z,\M5-)HY=WH7PZC6%#T%VH7SG.P8YXELHM:7.Z2HD@@95[C
MW_%9#,L23<DL?!0#L&<_?EA%U(W]4+)D4=[%>_ICP4C7YQ=MH9M?P5AAC<B+
M(5J)(:OOSDTYBH8I2Y<!1-8P+,MF,&3N(/@403305)[SZ$"DIJO%;1%>:"\@
MLB]*8(M8EE:"R&80N0T(LT-8Z#I^VXNM98*;?I^Y(/*!B5Z"R4H9 &<%>X:U
M6RT367,$Y:1WF@]:DKQ'!RZZ(1<'%]W<SU%C !=C,R(4L%"4+<9."2Z+X-()
MPY@$.T",44+,GB!&)8)V8N>#F#1O$8B9]>1-W7A;W+\+H5%&?DBY@RD@+F9[
M1DO!4I[ABB./]%P$]T+?C:/E(MOBJR3_#X)G97@@0B\@^+N ^X"4=>P^X4G(
MM.?5 KO,XZDQ?^'4> NGZ,SB./%2DH X<TJ5WN1$,I^W4J\E*%)]_29!SFYN
M49IY*O(2E>-UZZF .I*RIS-(:FT_TYUBBC6MF(OP]1NE&J*\Y;[&<1TZWKH%
MQ+7IGH7W9F.-8'N ;!:DZ_"SX/OB2(#YCFYW,NSY[LF&TP4_!C^RFY%<04@V
MOP-,/PTH_/*,Y44.Z,^$UEESM^V=\&@?5JPRYV=+IL&)K/3XV)N:I6:ED80!
M1SQ&'CKQ?#3" 7K$;LP.@+R6J?KCBB(=Z<E G\JA5FE<72U=8L[![^V,+"6Q
M95!DRX?DFOGB<HZ!S_PY1=D"?()V_N4'W]-ADY'X0->']L%N-0\&*5*EP0/>
M_P/QF)S(B0EB\>[??J%\K*Q>B3&*S#&FY.O+5;@H8BA*B1CYV*WE0@RUTI"@
MSXN(\9+KM3^>9FO;$4-+$*/DZXM5N#!BZ"5BY&.WG@LQ#(88.E";1PRUU.Q=
M6;T:,<P$,4J^OEB%"R-&K42,?.PV<B$&+/+80S4+@+$^?%^IV%LXO1(P5"D!
MC)*O+];@HH"ARB5@Y&.WF0<P5%CCR<N+$JV<"G=F]6K$4#EBE'Q]N0H71@RM
M1(Q\[*[E0@R=(8:YN"AA;T64FKT;JU<CAI$@AM4L&?M2'2X,&68)&?G8;>6"
MC!J#C*6]DA<%%OSQ--O:#AD6AXR2KR]7X:*(H4DE8N0\IRSE@0Q-9I"AF@N0
M892JO3NO5V*&IG#,*!F[!R4N#!KJ"T"CV%'P QY>9M&P;![$88)L'MT!6O0=
M/0T(#]6Z$'J!A@A:1Z"7#^PDX4/@/T4#=IQ^Q,(Q8!CXI ]5\%<%DFO$DHZ6
MWX1Y?@I&G9ZE9\$OS'-^HUC23UG,CN0HOM(3E!4D5CTKLTB+G<YGQ4_%/%$.
MIL>AJ<>"?-;5-SE,WE[#VX*1(_9VE66G9S6R3OS*^]!*NI#S%HNV_=;M@46R
M?$A_X]G['(F''-_]#2/V#,;IRN%/EX*N#&!P$Y?8$0QNS^>W&N*0\%R@"FEH
M%\B97#%!R2/"3.*\+G?"*G^B4#539@^Z!2D!>:0AE /(P)[-%!;;-@M'SS*'
M$?8<'#AA$M3%67>E0CW!TRL5LZ @)M%TIJJT!@#6C/BUXCN*RQ%63;2D71[X
MJ&UXWV/^X8X=WPTMKSKEN.JTF4GYGM@V*RL8N^I1[,-'$>M$9(@445)$A.Y(
M&+L1CX-X YB17LB#D8^^3$&AY0-(L83E:?Q]8>T]0!#UDEF.81,80=$ 3*9I
MAQG>9G'UVN,![=$(698H(QQ%&.#706!SD<@_8X96C[!L_3CP:,B2&%/" 4R7
M''][!&PM@'4'L2A^"O2(NL3AG^5SCKL,$ $Q82@0SM\I8M9RFU,L4TI^-D-:
MR^D9 W&?V8E/@.,HC'O_@3H8.K."+L4]ZB;D>84XFK9AJ2]T&OX?>@1S44#Z
MP D6F(UZ0(]-&MEDQ GP\*[\+F?6!$"CY"D]Q#DQ-UEL,#_]Y>N=9^PR"!GQ
M=[*>>T?&(Q8ZCL4KBW@K0;IA; _2D&7O73>;\QK&^C:O@9ZS30CSNLS7 C!/
MC*9AV#A_H)!+<$C.D,/)S#],> ;U>###VTRUDWAOV2@/GI&@[5*4Q+1FK4K-
MQZE._QWSE\I08G/\%GL$J5)"?B<AE)/1[I/1(><.6<_F#DN49)@[GF>(;H8&
MR=21*G984!WF3,+$(OL/Z"[M3PX? 0)6P5;A&%6R7C@N_SI2-5 8[6@"-^PG
M+/&FV(T95E[[8@%7V\?H^R4)[8".^&L]K^ -W\B$31C3[[^&+W$3)R[P2DN:
M),IQ_I9M0X. N6/^5A3#95-GB%T2 A@2#/:C]Q".Q$$$#&5S_445+X+]*ZMR
M*<7]2O&66UIWB:6UUF)*33 N[J/O,OH8W<C,X8_1FS.4F=TK$>6H+835^TRR
MI!W]_+^Z9RT?&H)N866!.FQG#U21O41QB2.,^%-R)V38(PY;<S$_+O=ML*R,
M$OKSE[NKZ0+\5,RQ__52%WJ96":6B67BJR:NWB4NX[4=E=_H_;_(T^W\>MV\
M_W;7[N[KS9A#6@_<+W>[X&T/R-\Q#5*?7+[MAK-56\Y.#&L:&\=LFYC[GP/^
M1 NKID=0"/R !+;5$K$-DP%V^\QQS0AQ8S;-P)SX)&8^;$X/Q]' #Z!WSOJ#
M(8LO9QW<!:CM%*:>N0#-S2]+Y'<-UO3:?IR)DF@8N9Z[6 !/6=^P'_T6CU7N
MYR5?F$<."C)\A+:O.NBJ<W7U%VI>7Z+6S=?;YO5?V_UY1]'CU9AT\OS2V<I'
MFA>53=E5V98?X]OWDZ?OAJ>_3.ISK'RS6,*'[CTW?:IA%5WZ'G8=U!31O_'W
MP'\*O]-#><7?1.+L>.P>93X3"D[B_=XA&-R[X<V/I@O\T/\/"@"< 5WB43]
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M%)N2_W0.NSXZ+8>>]R]S.-@]QS9EB.F^U0^FX0(IH/Y2W <%L!]IB.=P^^=
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M&4?$L"8L&. D(0!CK(5-I=94O 3K(_V_;IXQ3.N#)$$@Z4K14;=PX&%%2AG
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MM@$2+#+@[=Z%5KAQ@K(\XKFH5R64)!_#7Y,UERO5-F-,B$.P34V7,M_TF>O
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M[^T_ /CK7U].)\>962Y<6DZ.<J=*9R?7<7DY*2_=Y,\L_Q9_5Y.S1)4^RQ<
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M=TCUH&4XLCHZ&KL+0M>^P_():4D(+(8W5P54DS5I9'T_Q"L6D,CD !5@4@)
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MU7$#J8/J>S:J='5%I2:[[3T;^RROO_8L25V/?E?UZ.N*\'5%^%T"IZX(_QC
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M**_:U-GO^F<]:WO'(_:BK??3QRCDL@Y8,&+MSDL-6H_P'D"@:EAI&, _MO!
M&FILRH'MN.O.H.TH$C$;SI@;W(%8A1Y<6)S-IJ%C@9AD[U?]S. WL;(7;O^5
M1+$'GE:$:Q!1['@H;TF"AV)(GU$B YU9 ((8AE Q1Q8D<82@(6&-R\U!8O1,
M"9..;J:+QKF @@ \,3L$K>;C^+>!FX Z&(?!73QYP$(+7>#P*,.0FA"6&:9@
M?'SV\?KM>U0SOQF$5'T-=969,1;KK1^?,0C?F1)?YHEV6^*_G?.$MI( 'DOI
M&@[F)JBZX!=QZP1)!&]QWX<960+GA%=IXK6WB'R+1Y/&E,\.R"=+R%KTKML
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M) P%.KJ908#2POXKN471D(8GT DHJGO!0W?6D*+A^NH+&R5H5#3D9A10E9L
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M<(*V6[N_S1V;>P! 28CKY+BE;6J]7JL,W%)3P)$T9E\S^]TR4, )RLN.\?*
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MV3=!")[C-*!D8!;SK]D!M+-W,E$)?BO$3)^@##/J".3VAD:M/W<,T&ZM/K<
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MW-]A8,_@GTGLN3_\?U!+ 0(4 Q0    ( *-8!5VI.8UL$1,  ,VX   0
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M2P$"% ,4    " "C6 5=%C#D[B (   Z30  %               @ '_+0
M;&QY+3(P,C8P.# U7W!R92YX;6Q02P$"% ,4    " "C6 5=$DLYRX]!  #?
M6@, '@              @ %1-@  <3(R-FQI;&QY<V%L97-A;F1E87)N:6YG
<<W N:'1M4$L%!@     &  8 C@$  !QX      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>lly-20260805_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2026"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:lly="http://www.lilly.com/20260805"
  xmlns:us-gaap="http://fasb.org/us-gaap/2026"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="lly-20260805.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
        </entity>
        <period>
            <startDate>2026-08-05</startDate>
            <endDate>2026-08-05</endDate>
        </period>
    </context>
    <context id="c-2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-08-05</startDate>
            <endDate>2026-08-05</endDate>
        </period>
    </context>
    <context id="c-3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A2.125NotesDueJune32030Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-08-05</startDate>
            <endDate>2026-08-05</endDate>
        </period>
    </context>
    <context id="c-4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A625Notesdue2031Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-08-05</startDate>
            <endDate>2026-08-05</endDate>
        </period>
    </context>
    <context id="c-5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A500NotesDue2033Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-08-05</startDate>
            <endDate>2026-08-05</endDate>
        </period>
    </context>
    <context id="c-6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A6.77NotesDueJanuary12036Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-08-05</startDate>
            <endDate>2026-08-05</endDate>
        </period>
    </context>
    <context id="c-7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A1625NotesDue2043Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-08-05</startDate>
            <endDate>2026-08-05</endDate>
        </period>
    </context>
    <context id="c-8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A1.700Notesdue2049Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-08-05</startDate>
            <endDate>2026-08-05</endDate>
        </period>
    </context>
    <context id="c-9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A1125NotesDue2051Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-08-05</startDate>
            <endDate>2026-08-05</endDate>
        </period>
    </context>
    <context id="c-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A1375NotesDue2061Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-08-05</startDate>
            <endDate>2026-08-05</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-45">0000059478</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="c-1" id="f-46">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="c-1" id="f-1">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-2">2026-08-05</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="c-1" id="f-3">ELI LILLY AND COMPANY</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-4">IN</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">001-06351</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-6">35-0470950</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-7">Lilly Corporate Center</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-8">Indianapolis,</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-9">IN</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-10">46285</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-11">317</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-12">276-2000</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="c-1" id="f-13">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="c-1" id="f-14">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="c-1" id="f-15">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="c-1" id="f-16">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="c-2" id="f-17">Common Stock (no par value)</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-2" id="f-18">LLY</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-2" id="f-19">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle contextRef="c-3" id="f-20">2.125% Notes due 2030</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-3" id="f-21">LLY30</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-3" id="f-22">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle contextRef="c-4" id="f-23">0.625% Notes due 2031</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-4" id="f-24">LLY31</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-4" id="f-25">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle contextRef="c-5" id="f-26">0.500% Notes due 2033</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-5" id="f-27">LLY33</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-5" id="f-28">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle contextRef="c-6" id="f-29">6.77% Notes due 2036</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-6" id="f-30">LLY36</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-6" id="f-31">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle contextRef="c-7" id="f-32">1.625% Notes due 2043</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-7" id="f-33">LLY43</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-7" id="f-34">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle contextRef="c-8" id="f-35">1.700% Notes due 2049</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-8" id="f-36">LLY49A</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-8" id="f-37">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle contextRef="c-9" id="f-38">1.125% Notes due 2051</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-9" id="f-39">LLY51</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-9" id="f-40">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle contextRef="c-10" id="f-41">1.375% Notes due 2061</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-10" id="f-42">LLY61</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-10" id="f-43">NYSE</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-44">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
